Danaher (DHR) 10-Q 20 Jul 22 2022 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jul. 01, 2022	Jul. 15, 2022
Entity Information [Line Items]
Document type	10-Q
Document quarterly report	true
Document period end date	Jul. 01, 2022
Document transition report	false
Entity file number	001-08089
Entity registrant name	DANAHER CORPORATION
Entity incorporation, state code	DE
Entity tax identification number	59-1995548
Entity address, address line one	2200 Pennsylvania Avenue, N.W., Suite 800W
Entity address, postal zip code	20037-1701
Entity address, city	Washington,
Entity address, state	DC
City area code	202
Local phone number	828-0850
Entity current reporting status	Yes
Entity interactive data current	Yes
Entity filer category	Large Accelerated Filer
Entity small business	false
Entity emerging growth company	false
Entity shell company	false
Entity common stock, shares outstanding		727,445,355
Amendment flag	false
Document fiscal year focus	2022
Document fiscal period focus	Q2
Current fiscal year end date	--12-31
Entity central index key	0000313616
Common stock
Entity Information [Line Items]
Title of 12(b) security	Common stock, $0.01 par value
Trading symbol	DHR
Security exchange name	NYSE
5.00% Mandatory Convertible Preferred Stock, Series B, without par value
Entity Information [Line Items]
Title of 12(b) security	5.00% Mandatory Convertible Preferred Stock, Series B, without par value
Trading symbol	DHR.PRB
Security exchange name	NYSE
1.700% Senior Notes due 2024
Entity Information [Line Items]
Title of 12(b) security	1.700% Senior Notes due 2024
Trading symbol	DHR 24
Security exchange name	NYSE
0.200% Senior Notes due 2026
Entity Information [Line Items]
Title of 12(b) security	0.200% Senior Notes due 2026
Trading symbol	DHR/26
Security exchange name	NYSE
2.100% Senior Notes due 2026
Entity Information [Line Items]
Title of 12(b) security	2.100% Senior Notes due 2026
Trading symbol	DHR 26
Security exchange name	NYSE
1.200% Senior Notes due 2027
Entity Information [Line Items]
Title of 12(b) security	1.200% Senior Notes due 2027
Trading symbol	DHR/27
Security exchange name	NYSE
0.450% Senior Notes due 2028
Entity Information [Line Items]
Title of 12(b) security	0.450% Senior Notes due 2028
Trading symbol	DHR/28
Security exchange name	NYSE
2.500% Senior Notes due 2030
Entity Information [Line Items]
Title of 12(b) security	2.500% Senior Notes due 2030
Trading symbol	DHR 30
Security exchange name	NYSE
0.750% Senior Notes due 2031
Entity Information [Line Items]
Title of 12(b) security	0.750% Senior Notes due 2031
Trading symbol	DHR/31
Security exchange name	NYSE
1.350% Senior Notes due 2039
Entity Information [Line Items]
Title of 12(b) security	1.350% Senior Notes due 2039
Trading symbol	DHR/39
Security exchange name	NYSE
1.800% Senior Notes due 2049
Entity Information [Line Items]
Title of 12(b) security	1.800% Senior Notes due 2049
Trading symbol	DHR/49
Security exchange name	NYSE

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets - USD ($) $ in Millions	Jul. 01, 2022	Dec. 31, 2021
Current assets:
Cash and equivalents	$ 3,984	$ 2,586
Trade accounts receivable, less allowance for doubtful accounts of $120 and $124, respectively	4,527	4,631
Inventories:
Finished goods	1,608	1,343
Work in process	530	473
Raw materials	1,119	951
Total inventories	3,257	2,767
Prepaid expenses and other current assets	1,461	1,664
Total current assets	13,229	11,648
Property, plant and equipment, net of accumulated depreciation of $3,538 and $3,465, respectively	3,794	3,790
Other long-term assets	4,600	3,719
Goodwill	39,276	41,184
Other intangible assets, net	20,907	22,843
Total assets	81,806	83,184
Current liabilities:
Notes payable and current portion of long-term debt	10	8
Trade accounts payable	2,419	2,569
Accrued expenses and other liabilities	5,127	5,563
Total current liabilities	7,556	8,140
Other long-term liabilities	7,597	7,699
Long-term debt	20,052	22,168
Stockholders’ equity:
Preferred stock	1,668	3,268
Common stock	9	9
Additional paid-in capital	11,854	10,090
Retained earnings	35,808	32,827
Accumulated other comprehensive income (loss)	(2,745)	(1,027)
Total Danaher stockholders’ equity	46,594	45,167
Noncontrolling interests	7	10
Total stockholders’ equity	46,601	45,177
Total liabilities and stockholders’ equity	$ 81,806	$ 83,184

Consolidated Condensed Balanc_2

Consolidated Condensed Balance Sheets (Parenthetical) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Jul. 01, 2022	Dec. 31, 2021
Allowance for doubtful accounts	$ 120	$ 124
Property, plant and equipment, accumulated depreciation	$ 3,538	$ 3,465
Common stock, par value (in usd per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	2,000,000,000	2,000,000,000
Common stock, shares issued (in shares)	868,400,000	855,700,000
Common stock, shares outstanding (in shares)	727,400,000	715,000,000
Preferred stock
Preferred stock, no par value (in usd per share)	$ 0	$ 0
Preferred stock, shares authorized (in shares)	15,000,000	15,000,000
Preferred stock | Preferred stock series A
Preferred stock, shares issued (in shares)	0	1,650,000
Preferred stock, shares outstanding (in shares)	0	1,650,000
Preferred stock, dividend rate, percent	4.75%	4.75%
Preferred stock | 5.00% Mandatory Convertible Preferred Stock, Series B, without par value
Preferred stock, shares issued (in shares)	1,720,000	1,720,000
Preferred stock, shares outstanding (in shares)	1,720,000	1,720,000
Preferred stock, dividend rate, percent	5%	5%

Consolidated Condensed Statemen

Consolidated Condensed Statements of Earnings - USD ($) shares in Millions, $ in Millions	3 Months Ended			6 Months Ended
	Jul. 01, 2022	Jul. 02, 2021		Jul. 01, 2022	Jul. 02, 2021
Income Statement [Abstract]
Sales	$ 7,751	$ 7,218		$ 15,439	$ 14,076
Cost of sales	(3,030)	(2,821)		(6,013)	(5,426)
Gross profit	4,721	4,397		9,426	8,650
Operating costs:
Selling, general and administrative expenses	(2,085)	(1,966)		(4,177)	(3,842)
Research and development expenses	(431)	(426)		(872)	(806)
Operating profit	2,205	2,005		4,377	4,002
Nonoperating income (expense):
Other income (expense), net	(87)	97		(107)	237
Interest expense	(51)	(62)		(105)	(120)
Interest income	2	3		3	7
Earnings from continuing operations before income taxes	2,069	2,043		4,168	4,126
Income taxes	(389)	(344)		(763)	(725)
Net earnings from continuing operations	1,680	1,699		3,405	3,401
Earnings from discontinued operations, net of income taxes	0	86		0	86
Net earnings	1,680	1,785		3,405	3,487
Mandatory convertible preferred stock dividends	(22)	(41)		(63)	(82)
Net earnings attributable to common stockholders	$ 1,658	$ 1,744		$ 3,342	$ 3,405
Net earnings per common share from continuing operations:
Basic (in usd per share)	$ 2.28	$ 2.32		$ 4.63	$ 4.65
Diluted (in usd per share)	2.25	2.28		4.56	4.57
Net earnings per common share from discontinued operations:
Basic (in usd per share)	0	0.12		0	0.12
Diluted (in usd per share)	0	0.12		0	0.12
Net earnings per common share:
Basic (in usd per share)	2.28	2.44		4.63	4.77
Diluted (in usd per share)	$ 2.25	$ 2.40	[1]	$ 4.56	$ 4.68	[1]
Average common stock and common equivalent shares outstanding:
Basic (in shares)	726.7	714.5		721.5	713.9
Diluted (in shares)	736	736		736.8	735.6
[1]Net earnings per common share amounts do not add due to rounding. Net earnings per common share amounts for the relevant three-month periods do not add to the six-month period amount due to rounding.

Consolidated Condensed Statem_2

Consolidated Condensed Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2022	Jul. 02, 2021	Jul. 01, 2022	Jul. 02, 2021
Statement of Comprehensive Income [Abstract]
Net earnings	$ 1,680	$ 1,785	$ 3,405	$ 3,487
Other comprehensive income (loss), net of income taxes:
Foreign currency translation adjustments	(1,442)	408	(1,785)	(514)
Pension and postretirement plan benefit adjustments	7	11	21	21
Cash flow hedge adjustments	66	228	46	186
Total other comprehensive income (loss), net of income taxes	(1,369)	647	(1,718)	(307)
Comprehensive income	$ 311	$ 2,432	$ 1,687	$ 3,180

Consolidated Condensed Statem_3

Consolidated Condensed Statements of Stockholders' Equity - USD ($) $ in Millions	Total	Preferred stock	Common stock	Additional paid-in capital	Additional paid-in capital Preferred stock	Additional paid-in capital Liquid Yield Option Notes	Retained earnings	Accumulated other comprehensive income (loss)	Noncontrolling interests
Balance, beginning of period at Dec. 31, 2020		$ 3,268	$ 9	$ 9,698			$ 27,159	$ (368)	$ 11
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock-based award				158
Common stock issued in connection with Mandatory Convertible Preferred Stock conversions and LYONs’ conversions, including tax benefit of $10 for the six-month period ended July 2, 2021		0			$ 0	$ 34
Change in noncontrolling interests				0					(1)
Net earnings	$ 3,487						3,487
Common stock dividends declared							(300)
Mandatory Convertible Preferred Stock dividends declared							(82)
Other comprehensive income (loss)	(307)							(307)
Balance, end of period at Jul. 02, 2021	42,766	3,268	9	9,890			30,264	(675)	10
Balance, beginning of period at Apr. 02, 2021		3,268	9	9,794			28,670	(1,322)	11
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock-based award				96
Common stock issued in connection with Mandatory Convertible Preferred Stock conversions and LYONs’ conversions, including tax benefit of $10 for the six-month period ended July 2, 2021		0			0	0
Change in noncontrolling interests				0					(1)
Net earnings	1,785						1,785
Common stock dividends declared							(150)
Mandatory Convertible Preferred Stock dividends declared							(41)
Other comprehensive income (loss)	647							647
Balance, end of period at Jul. 02, 2021	42,766	3,268	9	9,890			30,264	(675)	10
Balance, beginning of period at Dec. 31, 2021	45,177	3,268	9	10,090			32,827	(1,027)	10
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock-based award				178
Common stock issued in connection with Mandatory Convertible Preferred Stock conversions and LYONs’ conversions, including tax benefit of $10 for the six-month period ended July 2, 2021		(1,600)			1,600	0
Change in noncontrolling interests				(14)					(3)
Net earnings	3,405						3,405
Common stock dividends declared							(361)
Mandatory Convertible Preferred Stock dividends declared							(63)
Other comprehensive income (loss)	(1,718)							(1,718)
Balance, end of period at Jul. 01, 2022	46,601	1,668	9	11,854			35,808	(2,745)	7
Balance, beginning of period at Apr. 01, 2022		3,268	9	10,123			34,332	(1,376)	6
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock-based award				130
Common stock issued in connection with Mandatory Convertible Preferred Stock conversions and LYONs’ conversions, including tax benefit of $10 for the six-month period ended July 2, 2021		(1,600)			$ 1,600	$ 0
Change in noncontrolling interests				1					1
Net earnings	1,680						1,680
Common stock dividends declared							(182)
Mandatory Convertible Preferred Stock dividends declared							(22)
Other comprehensive income (loss)	(1,369)							(1,369)
Balance, end of period at Jul. 01, 2022	$ 46,601	$ 1,668	$ 9	$ 11,854			$ 35,808	$ (2,745)	$ 7

Consolidated Condensed Statem_4

Consolidated Condensed Statements of Stockholders' Equity (Parenthetical) $ in Millions	6 Months Ended
	Jul. 02, 2021 USD ($)
Statement of Stockholders' Equity [Abstract]
Debt conversion, converted instrument, tax benefit	$ 10

Consolidated Condensed Statem_5

Consolidated Condensed Statements of Cash Flows - USD ($) $ in Millions	6 Months Ended
	Jul. 01, 2022	Jul. 02, 2021
Cash flows from operating activities:
Net earnings	$ 3,405	$ 3,487
Less: earnings from discontinued operations, net of income taxes	0	86
Net earnings from continuing operations	3,405	3,401
Noncash items:
Depreciation	358	336
Amortization of intangible assets	759	691
Amortization of acquisition-related inventory fair value step-up	0	29
Stock-based compensation expense	181	107
Pretax gain on sale of product lines and investment (gains) losses	122	(215)
Change in trade accounts receivable, net	(145)	(71)
Change in inventories	(668)	(292)
Change in trade accounts payable	(11)	(70)
Change in prepaid expenses and other assets	(99)	143
Change in accrued expenses and other liabilities	66	(68)
Net cash provided by operating activities from continuing operations	3,968	3,991
Cash flows from investing activities:
Cash paid for acquisitions	(77)	(1,065)
Payments for additions to property, plant and equipment	(546)	(556)
Proceeds from sales of property, plant and equipment	9	13
Payments for purchases of investments	(328)	(552)
Proceeds from sales of investments	17	56
Proceeds from sale of product lines	0	26
All other investing activities	22	18
Total cash used in investing activities for continuing operations	(903)	(2,060)
Cash flows from financing activities:
(Payments for) proceeds from the issuance of common stock in connection with stock-based compensation, net	(23)	25
Payment of dividends	(411)	(360)
Net (repayments of) proceeds from borrowings (maturities of 90 days or less)	(669)	13
Net repayments of borrowings (maturities longer than 90 days)	(265)	(279)
All other financing activities	(66)	13
Total cash used in financing activities for continuing operations	(1,434)	(588)
Effect of exchange rate changes on cash and equivalents	(233)	(56)
Net change in cash and equivalents	1,398	1,287
Beginning balance of cash and equivalents	2,586	6,035
Ending balance of cash and equivalents	3,984	7,322
Supplemental disclosures:
Cash interest payments	167	150
Cash income tax payments	$ 625	$ 568

General

General	6 Months Ended
	Jul. 01, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
General	GENERAL The Consolidated Condensed Financial Statements included herein have been prepared by Danaher Corporation (“Danaher” or the “Company”) without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). In this quarterly report, the terms “Danaher” or the “Company” refer to Danaher Corporation, Danaher Corporation and its consolidated subsidiaries, or the consolidated subsidiaries of Danaher Corporation, as the context requires. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to SEC rules and regulations; however, the Company believes that the disclosures are adequate to make the information presented not misleading. The Consolidated Condensed Financial Statements included herein should be read in conjunction with the financial statements as of and for the year ended December 31, 2021 and the Notes thereto included in the Company’s 2021 Annual Report on Form 10-K filed on February 23, 2022 (the “2021 Annual Report”). In the opinion of the Company, the accompanying financial statements contain all adjustments (consisting of only normal recurring accruals) necessary to present fairly the financial position of the Company as of July 1, 2022 and December 31, 2021, its results of operations for the three and six-month periods ended July 1, 2022 and July 2, 2021 and its cash flows for each of the six-month periods then ended. There have been no changes to the Company’s significant accounting policies described in the Company’s 2021 Annual Report that have a material impact on the Company’s Consolidated Condensed Financial Statements and the related Notes. Reclassifications of certain prior year amounts have been made to conform to the current year presentation. Accounting Standards Recently Adopted —In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The ASU includes amendments to the guidance on convertible instruments and the derivative scope exception for contracts in an entity’s own equity and simplifies the accounting for convertible instruments which include beneficial conversion features or cash conversion features by removing certain separation models in Subtopic 470-20. Additionally, the ASU requires entities to use the “if-converted” method when calculating diluted earnings per common share for convertible instruments. On January 1, 2022, the Company adopted the ASU and the ASU did not have a significant impact on the Company’s financial statements. In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832) , which requires annual disclosures of transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. For the Company, these disclosures will initially be required for the Company’s financial statements for the year ending December 31, 2022. These required annual disclosures include information on the nature of transactions and related accounting policies used to account for transactions, detail of the line items on the balance sheet and income statement affected by these transactions, including amounts applicable to each line, and significant terms and conditions of the transactions including commitments and contingencies. On January 1, 2022, the Company adopted the ASU. The Company is in the process of assessing the impact of this ASU and drafting the annual disclosures. In June 2022, the FASB issued ASU No. 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions . The ASU clarifies the guidance in ASC 820, Fair Value Measurement, related to the measurement of the fair value of an equity security subject to contractual sale restrictions and introduces disclosure requirements related to such equity securities. The Company early adopted the ASU effective July 1, 2022. The impact of the adoption of the ASU was not significant. Operating Leases —As of both July 1, 2022 and December 31, 2021, operating lease right-of-use assets where the Company was the lessee were approximately $1.0 billion and are included within other long-term assets in the accompanying Consolidated Condensed Balance Sheets. The associated operating lease liabilities were approximately $1.1 billion as of both July 1, 2022 and December 31, 2021 and are included in accrued expenses and other liabilities and other long-term liabilities.

Acquisitions

Acquisitions	6 Months Ended
	Jul. 01, 2022
Business Combination and Asset Acquisition [Abstract]
Acquisitions	ACQUISITIONS For a description of the Company’s acquisition activity for the year ended December 31, 2021, reference is made to the financial statements as of and for the year ended December 31, 2021 and Note 2 thereto included in the Company’s 2021 Annual Report. The Company continually evaluates potential acquisitions that either strategically fit with the Company’s existing portfolio or expand the Company’s portfolio into a new and attractive business area. The Company has completed a number of acquisitions that have been accounted for as purchases and have resulted in the recognition of goodwill in the Company’s financial statements. This goodwill arises because the purchase prices for these businesses exceed the fair value of acquired identifiable net assets due to a number of factors including the future earnings and cash flow potential of these businesses, the multiple to earnings, cash flow and other factors at which similar businesses have been purchased by other acquirers, the competitive nature of the processes by which the Company acquired the businesses, avoidance of the time and costs which would be required (and the associated risks that would be encountered) to enhance the Company’s existing product offerings to key target markets and enter into new and profitable businesses and the complementary strategic fit and resulting synergies these businesses bring to existing operations. The Company makes an initial allocation of the purchase price at the date of acquisition based upon its understanding of the fair value of the acquired assets and assumed liabilities. The Company obtains the information used for the purchase price allocation during due diligence and through other sources. In the months after closing, as the Company obtains additional information about these assets and liabilities, including through tangible and intangible asset appraisals, and learns more about the newly acquired business, it is able to refine the estimates of fair value and more accurately allocate the purchase price. The fair values of acquired intangibles are determined based on estimates and assumptions that are deemed reasonable by the Company. Significant assumptions include the discount rates and certain assumptions that form the basis of the forecasted results of the acquired business including earnings before interest, taxes, depreciation and amortization (“EBITDA”), revenue, revenue growth rates, royalty rates and technology obsolescence rates. These assumptions are forward looking and could be affected by future economic and market conditions. The Company engages third-party valuation specialists who review the Company’s critical assumptions and calculations of the fair value of acquired intangible assets in connection with significant acquisitions. Only facts and circumstances that existed as of the acquisition date are considered for subsequent adjustment. The Company is continuing to evaluate certain pre-acquisition contingencies associated with its 2021 and 2022 acquisitions and is also in the process of obtaining valuations of certain acquisition-related assets and liabilities in connection with these acquisitions. T he Company will make appropriate adjustments to the purchase price allocation prior to completion of the measurement period, as required. During the six-month period ended July 1, 2022, the Company acquired two businesses for total consideration of $77 million in cash, net of cash acquired. The businesses acquired complement existing units of the Company’s Life Science and Environmental & Applied Solutions segments. The aggregate annual sales of the two businesses acquired in 2022 at the time of acquisition, in each case based on the company’s revenues for its last completed fiscal year prior to the acquisition, were $7 million. The following summarizes the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition for the six-month period ended July 1, 2022 ($ in millions): Goodwill $ 44 Other intangible assets, primarily technology and customer relationships 35 Deferred tax liabilities (4) Other assets and liabilities, net 2 Net cash consideration $ 77 Pro Forma Financial Information The unaudited pro forma information for the periods set forth below gives effect to the 2021 and 2022 acquisitions as if they had occurred as of January 1, 2021. The pro forma information is presented for informational purposes only and is not necessarily indicative of the results of operations that actually would have been achieved had the acquisitions been consummated as of that time ( $ in millions, except per share amounts): Three-Month Period Ended Six-Month Period Ended July 1, 2022 July 2, 2021 July 1, 2022 July 2, 2021 Sales $ 7,751 $ 7,320 $ 15,440 $ 14,287 Net earnings from continuing operations 1,679 1,638 3,404 3,265 Diluted net earnings per common share from continuing operations (a) 2.25 2.20 4.56 4.38 (a) Diluted net earnings per common share from continuing operations is calculated by deducting the Mandatory Convertible Preferred Stock (“MCPS”) dividends from net earnings from continuing operations for the anti-dilutive MCPS shares (refer to Note 4 for additional information).

Discontinued Operations

Discontinued Operations	6 Months Ended
	Jul. 01, 2022
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	DISCONTINUED OPERATIONSOn July 2, 2016, the Company completed the separation of its former Test & Measurement segment, Industrial Technologies segment (excluding the product identification businesses) and retail/commercial petroleum business by distributing to Danaher stockholders on a pro rata basis all of the issued and outstanding common stock of Fortive Corporation (“Fortive”), the entity the Company incorporated to hold such businesses. For the three and six-month periods ended July 2, 2021, the Company recorded an income tax benefit of $86 million related to the release of previously provided reserves associated with uncertain tax positions on certain of the Company’s tax returns which were jointly filed with Fortive entities. These reserves were released due to the expiration of statutes of limitations for those returns. This income tax benefit is included in earnings from discontinued operations, net of income taxes in the accompanying Consolidated Condensed Statements of Earnings.

Net Earnings Per Common Share

Net Earnings Per Common Share	6 Months Ended
	Jul. 01, 2022
Earnings Per Share [Abstract]
Net Earnings Per Common Share	NET EARNINGS PER COMMON SHARE Basic net earnings per common share from continuing operations (“EPS”) is calculated by taking net earnings from continuing operations less the MCPS dividends divided by the weighted average number of common shares outstanding for the applicable period. Diluted net EPS from continuing operations is computed by taking net earnings from continuing operations less the MCPS dividends divided by the weighted average number of common shares outstanding increased by the number of additional shares that would have been outstanding had the potentially dilutive common shares been issued and reduced by the number of shares the Company could have repurchased with the proceeds from the issuance of the potentially dilutive shares. For the three-month periods ended July 1, 2022 and July 2, 2021, approximately 2.4 million and 193 thousand options to purchase shares, respectively, were excluded from the diluted EPS from continuing operations calculation and for the six-month periods ended July 1, 2022 and July 2, 2021, approximately 2.4 million and 132 thousand options, respectively, to purchase shares were excluded from the diluted EPS calculation, as the impact of their inclusion would have been anti-dilutive. Basic and diluted EPS are computed independently for each quarter and year-to-date period, and each period involves the use of different weighted-average share count figures. As a result, and after factoring the effect of rounding to the nearest cent per share, the sum of prior quarterly EPS figures may not equal year-to-date EPS. The impact of the MCPS Series A calculated under the if-converted method was dilutive for both the three and six-month periods ended July 1, 2022 and July 2, 2021, and as such 1.1 million and 6.0 million shares for the three and six-month periods ended July 1, 2022, respectively, and 11.0 million shares, for both the three and six-month periods ended July 2, 2021, underlying the MCPS Series A were included in the calculation of diluted EPS. The related MCPS Series A dividends of $20 million for the six-month period ended July 1, 2022 and $20 million and $40 million for the three and six-month periods ended July 2, 2021, respectively, were excluded from the calculation of net earnings for diluted EPS. On April 15, 2022, all outstanding shares of the MCPS Series A converted into 11.0 million shares of the Company’s common stock. There were no MCPS Series A dividends declared in the second quarter of 2022 prior to their conversion and the MCPS Series A were dilutive for all periods prior to the conversion. Refer to Note 15 for additional information about the MCPS Series A conversion. The impact of the MCPS Series B calculated under the if-converted method was anti-dilutive for both the three and six-month periods ended July 1, 2022 and July 2, 2021, and as such 8.6 million shares, for both the three and six-month periods underlying the MCPS Series B were excluded from the calculation of diluted EPS and the related MCPS Series B dividends of $22 million and $21 million for the three-month periods, respectively, and $43 million and $42 million for the six-month periods, respectively, were included in the calculation of net earnings for diluted EPS. Information related to the calculation of net earnings per common share from continuing operations is summarized as follows ($ and shares in millions, except per share amounts): Three-Month Period Ended Six-Month Period Ended July 1, 2022 July 2, 2021 July 1, 2022 July 2, 2021 Numerator: Net earnings from continuing operations $ 1,680 $ 1,699 $ 3,405 $ 3,401 MCPS dividends (22) (41) (63) (82) Net earnings from continuing operations attributable to common stockholders for Basic EPS 1,658 1,658 3,342 3,319 Adjustment for MCPS dividends for dilutive MCPS — 20 20 40 Net earnings from continuing operations attributable to common stockholders after assumed conversions for Diluted EPS $ 1,658 $ 1,678 $ 3,362 $ 3,359 Denominator: Weighted average common shares outstanding used in Basic EPS 726.7 714.5 721.5 713.9 Incremental common shares from: Assumed exercise of dilutive options and vesting of dilutive RSUs and PSUs 8.2 10.5 9.3 10.6 Assumed conversion of the convertible debentures — — — 0.1 Weighted average MCPS converted shares 1.1 11.0 6.0 11.0 Weighted average common shares outstanding used in Diluted EPS 736.0 736.0 736.8 735.6 Basic EPS from continuing operations $ 2.28 $ 2.32 $ 4.63 $ 4.65 Diluted EPS from continuing operations $ 2.25 $ 2.28 $ 4.56 $ 4.57

Revenue

Revenue	6 Months Ended
	Jul. 01, 2022
Revenue from Contract with Customer [Abstract]
Revenue	REVENUE The following tables present the Company’s revenues disaggregated by geographical region and revenue type for the three and six-month periods ended July 1, 2022 and July 2, 2021 ($ in millions) . Sales taxes and other usage-based taxes collected from customers are excluded from revenue. Life Sciences Diagnostics Environmental & Applied Solutions Total For the Three-Month Period Ended July 1, 2022: Geographical region: North America (b) $ 1,576 $ 1,235 $ 571 $ 3,382 Western Europe 972 453 266 1,691 Other developed markets 199 115 32 346 High-growth markets (a) 1,220 758 354 2,332 Total $ 3,967 $ 2,561 $ 1,223 $ 7,751 Revenue type: Recurring $ 2,872 $ 2,301 $ 719 $ 5,892 Nonrecurring 1,095 260 504 1,859 Total $ 3,967 $ 2,561 $ 1,223 $ 7,751 For the Three-Month Period Ended July 2, 2021: Geographical region: North America (b) $ 1,349 $ 970 $ 497 $ 2,816 Western Europe 1,052 443 275 1,770 Other developed markets 209 111 30 350 High-growth markets (a) 1,124 812 346 2,282 Total $ 3,734 $ 2,336 $ 1,148 $ 7,218 Revenue type: Recurring $ 2,640 $ 2,022 $ 658 $ 5,320 Nonrecurring 1,094 314 490 1,898 Total $ 3,734 $ 2,336 $ 1,148 $ 7,218 Life Sciences Diagnostics Environmental & Applied Solutions Total For the Six-Month Period Ended July 1, 2022: Geographical region: North America (b) $ 3,096 $ 2,541 $ 1,099 $ 6,736 Western Europe 2,007 977 535 3,519 Other developed markets 421 239 64 724 High-growth markets (a) 2,325 1,448 687 4,460 Total $ 7,849 $ 5,205 $ 2,385 $ 15,439 Revenue type: Recurring $ 5,710 $ 4,671 $ 1,409 $ 11,790 Nonrecurring 2,139 534 976 3,649 Total $ 7,849 $ 5,205 $ 2,385 $ 15,439 For the Six-Month Period Ended July 2, 2021: Geographical region: North America (b) $ 2,612 $ 1,942 $ 989 $ 5,543 Western Europe 2,022 858 554 3,434 Other developed markets 434 229 59 722 High-growth markets (a) 2,212 1,485 680 4,377 Total $ 7,280 $ 4,514 $ 2,282 $ 14,076 Revenue type: Recurring $ 5,169 $ 3,924 $ 1,306 $ 10,399 Nonrecurring 2,111 590 976 3,677 Total $ 7,280 $ 4,514 $ 2,282 $ 14,076 (a) The Company defines high-growth markets as developing markets of the world experiencing extended periods of accelerated growth in gross domestic product and infrastructure which include Eastern Europe, the Middle East, Africa, Latin America and Asia (with the exception of Japan, Australia and New Zealand). The Company defines developed markets as all markets that are not high-growth markets. (b ) The Company defines North America as the United States and Canada. The Company sells equipment to customers as well as consumables and services, some of which customers purchase on a recurring basis. Consumables sold for use with the equipment sold by the Company are typically critical to the use of the equipment and are typically used on a one-time or limited basis, requiring frequent replacement in the customer’s operating cycle. Examples of these consumables include reagents used in diagnostic tests, chromatography resins used for research and bioprocessing, filters used in filtration, separation and purification processes and cartridges for marking and coding equipment. Additionally, some of the Company’s consumables are used on a standalone basis, such as water treatment solutions. The Company separates its goods and services between those typically sold to a customer on a recurring basis and those typically sold on a nonrecurring basis. Recurring revenue includes revenue from consumables, services and operating-type leases (“OTLs”). Nonrecurring revenue includes sales from equipment and sales-type leases (“STLs”). OTLs and STLs are included in the above revenue amounts. For both the three-month periods ended July 1, 2022 and July 2, 2021, lease revenue was $117 million. For the six-month periods ended July 1, 2022 and July 2, 2021, lease revenue was $241 million and $234 million, respectively. Remaining performance obligations related to Topic 606, Revenue from Contracts with Customers, represent the aggregate transaction price allocated to performance obligations with an original contract term greater than one year which are fully or partially unsatisfied at the end of the period. As of July 1, 2022, the aggregate amount of the transaction price allocated to remaining performance obligations was approximately $4.8 billion. The Company expects to recognize revenue on approximately 60% of the remaining performance obligations over the next 12 months, 24% over the subsequent 12 months, and the remainder recognized thereafter. The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (“contract assets”) and deferred revenue, customer deposits and billings in excess of revenue recognized (“contract liabilities”) on the Consolidated Condensed Balance Sheets. Most of the Company’s long-term contracts are billed as work progresses in accordance with the contract terms and conditions, either at periodic intervals or upon achievement of certain milestones. Often this results in billing occurring subsequent to revenue recognition resulting in contract assets. Contract assets are generally classified as other current assets in the Consolidated Condensed Balance Sheets. The balance of contract assets as of July 1, 2022 and December 31, 2021 was $88 million and $75 million, respectively. The Company often receives cash payments from customers in advance of the Company’s performance resulting in contract liabilities that are classified as either current or long-term in the Consolidated Condensed Balance Sheets based on the timing of when the Company expects to recognize revenue. As of July 1, 2022 and December 31, 2021, contract liabilities were approximately $2.0 billion and $1.8 billion, respectively, and are included within accrued expenses and other liabilities and other long-term liabilities in the accompanying Consolidated Condensed Balance Sheets. The increase in the contract liability balance during the six-month period ended July 1, 2022 was primarily a result of cash payments received in advance of satisfying performance obligations, partially offset by revenue recognized during the period that was included in the opening contract liability balance and the impact of foreign currency. Revenue recognized during the six-month periods ended July 1, 2022 and July 2, 2021 that was included in the contract liability balance on December 31, 2021 and December 31, 2020 was $995 million and $775 million, respectively. Contract assets and liabilities are reported on a net basis on the accompanying Consolidated Condensed Balance Sheets on a contract-by-contract basis at the end of each reporting period.

Segment Information

Segment Information	6 Months Ended
	Jul. 01, 2022
Segment Reporting [Abstract]
Segment Information	SEGMENT INFORMATION The Company operates and reports its results in three separate business segments consisting of the Life Sciences, Diagnostics, and Environmental & Applied Solutions segments. When determining the reportable segments, the Company aggregated operating segments based on their similar economic and operating characteristics. Operating profit represents total revenues less operating expenses, excluding nonoperating income and expense, interest and income taxes. Operating profit amounts in the Other segment consist of unallocated corporate costs and other costs not considered part of management’s evaluation of reportable segment operating performance. Intersegment amounts are not significant and are eliminated to arrive at consolidated totals. Segment results are shown below ($ in millions): Three-Month Period Ended Six-Month Period Ended July 1, 2022 July 2, 2021 July 1, 2022 July 2, 2021 Sales: Life Sciences $ 3,967 $ 3,734 $ 7,849 $ 7,280 Diagnostics 2,561 2,336 5,205 4,514 Environmental & Applied Solutions 1,223 1,148 2,385 2,282 Total $ 7,751 $ 7,218 $ 15,439 $ 14,076 Operating profit: Life Sciences $ 1,174 $ 1,144 $ 2,292 $ 2,295 Diagnostics 800 649 1,686 1,275 Environmental & Applied Solutions 307 280 543 565 Other (76) (68) (144) (133) Total $ 2,205 $ 2,005 $ 4,377 $ 4,002

Income Taxes

Income Taxes	6 Months Ended
	Jul. 01, 2022
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES The following table summarizes the Company’s effective tax rate: Three-Month Period Ended Six-Month Period Ended July 1, 2022 July 2, 2021 July 1, 2022 July 2, 2021 Effective tax rate 18.8 % 16.8 % 18.3 % 17.6 % The Company operates globally, including in certain jurisdictions with lower tax rates than the United States (“U.S.”) federal statutory rate. Therefore, the impact of operating in such jurisdictions reduces the effective tax rate compared to the U.S. federal statutory tax rate. The effective tax rate for the three-month period ended July 1, 2022 differs from the U.S. federal statutory rate of 21.0% principally due the geographic mix of earnings described above and net discrete benefits of $8 million related primarily to changes in estimates associated with prior period uncertain tax positions and excess tax benefits from stock-based compensation. The net discrete benefits reduced the effective tax rate by 0.4% for the three-month period ended July 1, 2022. The effective tax rate for the six-month period ended July 1, 2022 differs from the U.S. federal statutory rate of 21.0% principally due to the geographic mix of earnings described above and net discrete benefits of $49 million related primarily to excess tax benefits from stock-based compensation and changes in estimates associated with prior period uncertain tax positions. The net discrete benefits reduced the effective tax rate by 1.2% for the six-month period ended July 1, 2022. The effective tax rate for the three-month period ended July 2, 2021 differs from the U.S. federal statutory rate of 21.0% principally due to net discrete benefits of $76 million related primarily to the release of reserves for uncertain tax positions due to the expiration of statutes of limitation, audit settlements and excess tax benefits from stock-based compensation, net of changes in estimates associated with prior period uncertain tax positions. These factors reduced the effective tax rate by 3.7% for the three-month period ended July 2, 2021. The effective tax rate for the six-month period ended July 2, 2021 differs from the U.S. federal statutory rate of 21.0% principally due to net discrete benefits of $120 million related primarily to release of reserves for uncertain tax positions due to the expiration of statutes of limitation, audit settlements and excess tax benefits from stock-based compensation, net of changes in estimates associated with prior period uncertain tax positions. These factors reduced the effective tax rate by 2.9% for the six-month period ended July 2, 2021. For a description of the Company’s significant tax matters, reference is made to the financial statements as of and for the year ended December 31, 2021 and Note 7 thereto included in the Company’s 2021 Annual Report.

Other Income (Expense), Net

Other Income (Expense), Net	6 Months Ended
	Jul. 01, 2022
Other Income and Expenses [Abstract]
Other Income (Expense), Net	OTHER INCOME (EXPENSE), NET The following sets forth the components of the Company’s other income (expense), net ($ in millions): Three-Month Period Ended Six-Month Period Ended July 1, 2022 July 2, 2021 July 1, 2022 July 2, 2021 Other components of net periodic benefit costs $ 11 $ 11 $ 15 $ 22 Investment gains (losses): Realized investment gains (losses) 27 11 64 38 Unrealized investment gains (losses) (125) 75 (186) 164 Total investment gains (losses) (98) 86 (122) 202 Gain on sale of product lines — — — 13 Total other income (expense), net $ (87) $ 97 $ (107) $ 237 Other Components of Net Periodic Benefit Costs The Company disaggregates the service cost component of net periodic benefit costs of the noncontributory defined benefit pension plans and other postretirement employee benefit plans and presents the other components of net periodic benefit costs in other income (expense), net. These other components of net periodic benefit costs include the assumed rate of return on plan assets, partially offset by amortization of actuarial losses and interest. The Company’s net periodic benefit costs for the six-month period ended July 1, 2022 includes a settlement loss of $10 million ($9 million after-tax) as a result of the transfer of a portion of its non-U.S. pension liabilities related to one defined benefit plan to a third-party. Investment Gains (Losses) The Company estimates the fair value of its investments in equity securities using the Fair Value Alternative and records adjustments to fair value within net earnings. Additionally, the Company is a limited partner in partnerships that invest primarily in early-stage companies. While the partnerships record these investments at fair value, the Company’s investments in the partnerships are accounted for under the equity method of accounting. The investment gains (losses) include realized and unrealized gains and losses related to changes in the fair value of the Company’s investments in equity securities and the Company’s equity in earnings of the partnerships that reflect the changes in fair value of the investments of the partnerships. Gain on Sale of Product Lines During the first quarter of 2021, the Company divested certain product lines for a cash purchase price, net of cash transferred and transaction costs, of $26 million and recognized a pretax gain on sale of $13 million ($10 million after-tax). The divested product lines generated revenues of approximately $88 million in the Environmental & Applied Solutions segment in 2020. The divestiture of these product lines did not represent a strategic shift with a major effect on the Company’s operations and financial results and therefore is not reported as a discontinued operation.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	6 Months Ended
	Jul. 01, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	GOODWILL AND OTHER INTANGIBLE ASSETS The following is a rollforward of the Company’s goodwill ($ in millions): Balance, December 31, 2021 $ 41,184 Attributable to 2022 acquisitions 44 Adjustments due to finalization of purchase price allocations (15) Foreign currency translation and other (1,937) Balance, July 1, 2022 $ 39,276 The carrying value of goodwill by segment is summarized as follows ($ in millions): July 1, 2022 December 31, 2021 Life Sciences $ 30,003 $ 31,638 Diagnostics 6,843 7,044 Environmental & Applied Solutions 2,430 2,502 Total $ 39,276 $ 41,184 The Company has not identified any “triggering” events which indicate an impairment of goodwill in 2022.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jul. 01, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTSAccounting standards define fair value based on an exit price model, establish a framework for measuring fair value where the Company’s assets and liabilities are required to be carried at fair value and provide for certain disclosures related to the valuation methods used within a valuation hierarchy as established within the accounting standards. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in markets that are not active, or other observable characteristics for the asset or liability, including interest rates, yield curves and credit risks, or inputs that are derived principally from, or corroborated by, observable market data through correlation. Level 3 inputs are unobservable inputs based on the Company’s assumptions. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement in its entirety. A summary of financial assets and liabilities that are measured at fair value on a recurring basis were as follows ($ in millions): Balance Quoted Prices in Active Market (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) July 1, 2022 December 31, 2021 July 1, 2022 December 31, 2021 July 1, 2022 December 31, 2021 July 1, 2022 December 31, 2021 Assets: Available-for-sale debt securities $ 15 $ 20 $ — $ — $ 15 $ 20 $ — $ — Investment in equity securities 316 336 26 88 — — — — Cross-currency swap derivative contracts 823 50 — — 823 50 — — Available-for-sale debt securities, which are included in other long-term assets in the accompanying Consolidated Condensed Balance Sheets, are measured at fair value using quoted prices reported by investment brokers and dealers based on the underlying terms of the security and comparison to similar securities traded on an active market. As of July 1, 2022 and December 31, 2021, available-for-sale debt securities primarily included U.S. Treasury Notes and corporate debt securities. The Company’s investments in equity securities consist of investments in publicly traded equity securities and investments in non-marketable equity securities. The publicly traded securities are classified as Level 1 in the fair value hierarchy as they are measured based on quotes in active markets. For the non-marketable equity securities, the Company estimates the fair value of the investments in equity securities based on the measurement alternative and adjusts for impairments and observable price changes with a same or similar security from the same issuer within net earnings (the “Fair Value Alternative”). The Company’s investments in these equity securities are not classified in the fair value hierarchy due to the use of these measurement methods. Additionally, the Company is a limited partner in partnerships that invest primarily in early-stage companies. While the partnerships record these investments at fair value, the Company’s investments in the partnerships are accounted for under the equity method of accounting and are not subject to fair value measurement disclosures. As of July 1, 2022 and December 31, 2021, the Company’s equity method investments included investments in partnerships with a carrying value of approximately $1.5 billion and $1.3 billion, respectively. During the three and six-month periods ended July 1, 2022, the Company recorded net realized and unrealized losses of $98 million and $122 million, respectively, and during the three and six-month periods ended July 2, 2021, the Company recorded net realized and unrealized gains of $86 million and $202 million, respectively, related to changes in the fair value of the Company’s investments in equity securities and the Company’s equity in earnings of the partnerships that reflect the changes in fair value of the investments of the partnerships. Refer to Note 8 for additional information on gains and losses on the Company’s investments including investments in the partnerships. These gains and losses are reflected in other income (expense), net in the Company’s Consolidated Condensed Statements of Earnings. The cross-currency swap derivative contracts are used to partially hedge the Company’s net investments in non-U.S. operations against adverse movements in exchange rates between the U.S. dollar and the Danish kroner, Japanese yen, euro and Swiss franc. The Company also uses cross-currency swap derivative contracts to hedge the exchange rate exposure from long-term debt issuances in a foreign currency other than the functional currency of the borrower. The cross-currency swap derivative contracts are classified as Level 2 in the fair value hierarchy as they are measured using the income approach with the relevant interest rates and foreign currency current exchange rates and forward curves as inputs. Refer to Note 12 for additional information. Fair Value of Other Financial Instruments The carrying amounts and fair values of the Company’s other financial instruments were as follows ($ in millions): July 1, 2022 December 31, 2021 Carrying Amount Fair Value Carrying Amount Fair Value Debt obligations: Notes payable and current portion of long-term debt $ 10 $ 10 $ 8 $ 8 Long-term debt 20,052 17,706 22,168 22,796 As of July 1, 2022 and December 31, 2021, short and long-term borrowings were categorized as Level 1. The fair value of long-term borrowings was based on quoted market prices. The difference between the fair value and the carrying amounts of long-term borrowings is attributable to changes in market interest rates and/or the Company’s credit ratings subsequent to the incurrence of the borrowing. The fair values of borrowings with original maturities of one year or less, as well as cash and cash

Financing

Financing	6 Months Ended
	Jul. 01, 2022
Debt Disclosure [Abstract]
Financing	FINANCING As of July 1, 2022, the Company was in compliance with all of its debt covenants. The components of the Company’s debt were as follows ($ in millions): Description and Aggregate Principal Amount July 1, 2022 December 31, 2021 U.S. dollar-denominated commercial paper $ — $ 1,440 Euro-denominated commercial paper (€1.9 billion and €1.2 billion, respectively) 2,008 1,366 Floating rate senior unsecured notes due 6/30/2022 (€250 million) (the “Floating Rate 2022 Euronotes”) — 284 2.05% senior unsecured notes due 11/15/2022 (the “2022 Biopharma Notes”) 700 699 0.5% senior unsecured bonds due 12/08/2023 (CHF 540 million) (the “2023 CHF Bonds”) 563 592 1.7% senior unsecured notes due 3/30/2024 (€900 million) (the “2024 Euronotes”) 936 1,021 2.2% senior unsecured notes due 11/15/2024 (the “2024 Biopharma Notes”) 698 698 3.35% senior unsecured notes due 9/15/2025 (the “2025 U.S. Notes”) 498 498 0.2% senior unsecured notes due 3/18/2026 (€1.3 billion) (the “2026 Biopharma Euronotes”) 1,298 1,416 2.1% senior unsecured notes due 9/30/2026 (€800 million) (the “2026 Euronotes”) 832 907 0.3% senior unsecured notes due 5/11/2027 (¥30.8 billion) (the “2027 Yen Notes”) 227 267 1.2% senior unsecured notes due 6/30/2027 (€600 million) (the “2027 Euronotes”) 624 680 0.45% senior unsecured notes due 3/18/2028 (€1.3 billion) (the “2028 Biopharma Euronotes”) 1,296 1,413 1.125% senior unsecured bonds due 12/08/2028 (CHF 210 million) (the “2028 CHF Bonds”) 222 233 2.6% senior unsecured notes due 11/15/2029 (the “2029 Biopharma Notes”) 796 795 2.5% senior unsecured notes due 3/30/2030 (€800 million) (the “2030 Euronotes”) 834 910 0.75% senior unsecured notes due 9/18/2031 (€1.8 billion) (the “2031 Biopharma Euronotes”) 1,814 1,980 0.65% senior unsecured notes due 5/11/2032 (¥53.2 billion) (the “2032 Yen Notes”) 392 461 1.35% senior unsecured notes due 9/18/2039 (€1.3 billion) (the “2039 Biopharma Euronotes”) 1,288 1,406 3.25% senior unsecured notes due 11/15/2039 (the “2039 Biopharma Notes”) 890 890 4.375% senior unsecured notes due 9/15/2045 (the “2045 U.S. Notes”) 499 499 1.8% senior unsecured notes due 9/18/2049 (€750 million) (the “2049 Biopharma Euronotes”) 773 844 3.4% senior unsecured notes due 11/15/2049 (the “2049 Biopharma Notes”) 889 889 2.6% senior unsecured notes due 10/01/2050 (the “2050 U.S. Notes”) 980 980 2.8% senior unsecured notes due 12/10/2051 (the “2051 U.S. Notes”) 984 983 Other 21 25 Total debt 20,062 22,176 Less: currently payable (10) (8) Long-term debt $ 20,052 $ 22,168 For additional details regarding the Company’s debt financing, refer to Note 14 of the Company’s financial statements as of and for the year ended December 31, 2021 included in the Company’s 2021 Annual Report. The Company has historically satisfied short-term liquidity needs that are not met through operating cash flow and available cash primarily through issuances of commercial paper under its U.S. dollar and euro-denominated commercial paper programs. The Company ’s $5.0 billion u nsecured, multi-year revolving credit facility with a syndicate of banks that expires on August 27, 2024 (the “Five-Year Facility”), is available for direct borrowings and provides credit support for the commercial paper programs. For a description of the Five-Year Facility, refer to the Company’s 2021 Annual Report. On February 21, 2022, the Company and the syndicate of banks amended the Five-Year Facility to replace references to the London Interbank Offered Rate with references to the Sterling Overnight Index Average Reference Rate, the Tokyo Interbank Offer Rate or the Euro Interbank Offer Rate depending on the applicable currency of the borrowing. As of July 1, 2022, borrowings outstanding under the Company’s euro-denominated commercial paper program had a weighted average annual interest rate of negative 0.2% and a weighted average remaining maturity of approximately 25 days. On June 30, 2022, the Company repaid the €250 million aggregate principal amount of the Floating Rate 2022 Euronotes upon their maturity using available cash. Debt discounts, premiums and debt issuance costs totaled $123 million and $130 million as of July 1, 2022 and December 31, 2021, respectively, and have been netted against the aggregate principal amounts of the related debt in the components of debt table above. Guarantors of Debt The Company has guaranteed long-term debt and commercial paper issued by certain of its wholly-owned subsidiaries. The Floating Rate 2022 Euronotes (prior to repayment in the second quarter of 2022) and 2027 Euronotes were issued by DH Europe Finance S.A. (“Danaher International”). The 2022 Biopharma Notes, 2024 Biopharma Notes, 2026 Biopharma Euronotes, 2028 Biopharma Euronotes, 2029 Biopharma Notes, 2031 Biopharma Euronotes, 2039 Biopharma Euronotes, 2039 Biopharma Notes, 2049 Biopharma Euronotes and 2049 Biopharma Notes and euro-denominated commercial paper were issued by DH Europe Finance II S.a.r.l. (“Danaher International II”). The 2023 CHF Bonds and 2028 CHF Bonds were issued by DH Switzerland Finance S.A. (“Danaher Switzerland”). The 2027 Yen Notes and 2032 Yen Notes were issued by DH Japan Finance S.A. (“Danaher Japan”). Each of Danaher International, Danaher International II, Danaher Switzerland and Danaher Japan are wholly-owned finance subsidiaries of Danaher Corporation. All of the outstanding and future securities issued by each of these entities are or will be fully and unconditionally guaranteed by the Company and these guarantees rank on parity with the Company’s unsecured and unsubordinated indebtedness .

Hedging Transactions and Deriva

Hedging Transactions and Derivative Financial Instruments	6 Months Ended
	Jul. 01, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Hedging Transactions and Derivative Financial Instruments	HEDGING TRANSACTIONS AND DERIVATIVE FINANCIAL INSTRUMENTS The Company uses cross-currency swap derivative contracts to partially hedge its net investments in non-U.S. operations against adverse movements in exchange rates between the U.S. dollar and the Danish kroner, Japanese yen, euro and Swiss franc. The cross-currency swap derivative contracts are agreements to exchange fixed-rate payments in one currency for fixed-rate payments in another currency. These contracts effectively convert U.S. dollar-denominated bonds to obligations denominated in Danish kroner, Japanese yen, euro and Swiss franc, and partially offset the impact of changes in currency rates on the Company’s foreign currency denominated net investments. These contracts also reduce the interest rate from the stated interest rates on the U.S. dollar-denominated debt to the interest rates of the swaps. The changes in the spot rate of these instruments are recorded in accumulated other comprehensive income (loss) in stockholders’ equity, partially offsetting the foreign currency translation adjustment of the Company’s related net investment that is also recorded in accumulated other comprehensive income (loss). Any ineffective portions of net investment hedges are reclassified from accumulated other comprehensive income (loss) into earnings during the period of change. The interest income or expense from these swaps are recorded in interest expense in the accompanying Consolidated Condensed Statements of Earnings consistent with the classification of interest expense attributable to the underlying debt. These instruments mature on dates ranging from September 2025 to December 2031. The Company also uses cross-currency swap derivative contracts to hedge U.S. dollar-denominated long-term debt issuances in a foreign subsidiary whose functional currency is the euro against adverse movements in exchange rates between the U.S. dollar and the euro. These contracts effectively convert these U.S. dollar-denominated bonds to obligations denominated in euro. The changes in the fair value of these instruments are recorded in accumulated other comprehensive income (loss), with a reclassification from accumulated other comprehensive income (loss) to net earnings to offset the remeasurement of the hedged debt that is also recorded in net earnings. Any ineffective portions of the cash flow hedges are reclassified from accumulated other comprehensive income (loss) into earnings during the period of change. The interest income or expense from these swaps are recorded in interest expense in the accompanying Consolidated Condensed Statements of Earnings consistent with the classification of interest expense attributable to the underlying debt. These instruments mature on dates ranging from November 2022 to November 2049. The Company has also issued foreign currency denominated long-term debt as partial hedges of its net investments in foreign operations against adverse movements in exchange rates between the U.S. dollar and the euro, Japanese yen and Swiss franc. These foreign currency denominated long-term debt issuances are designated and qualify as nonderivative hedging instruments. Accordingly, the foreign currency translation of these debt instruments is recorded in accumulated other comprehensive income (loss), offsetting the foreign currency translation adjustment of the Company’s related net investment that is also recorded in accumulated other comprehensive income (loss). Any ineffective portions of net investment hedges are reclassified from accumulated other comprehensive income (loss) into earnings during the period of change. These instruments mature on dates ranging from July 2022 to May 2032. The Company used interest rate swap agreements to hedge the variability in cash flows due to changes in benchmark interest rates related to a portion of the U.S. debt the Company issued to fund the acquisition of Cytiva and a portion of the 2051 Notes. These contracts effectively fixed the interest rate for a portion of the Company’s U.S. dollar-denominated debt equal to the notional amount of the swaps to the rate specified in the interest rate swap agreements and were settled in November 2019 and December 2021, respectively. The changes in the fair value of these instruments were recorded in accumulated other comprehensive income (loss) prior to the issuance of the debt and are subsequently being reclassified to interest expense over the life of the related debt. The following table summarizes the notional values as of July 1, 2022 and July 2, 2021 and pretax impact of changes in the fair values of instruments designated as net investment hedges and cash flow hedges in accumulated other comprehensive income (“OCI”) for the three and six-month periods ended July 1, 2022 and July 2, 2021 ($ in millions): Original Notional Amount Notional Amount Outstanding Gain (Loss) Recognized in OCI Amounts Reclassified from OCI For the Three-Month Period Ended July 1, 2022: Net investment hedges: Cross-currency contracts $ 3,875 $ 3,000 $ 216 $ — Foreign currency denominated debt 5,870 5,870 271 — Cash flow hedges: Cross-currency contracts 4,000 4,000 381 (224) Interest rate swaps 1,600 — — 1 Total $ 15,345 $ 12,870 $ 868 $ (223) For the Three-Month Period Ended July 2, 2021: Net investment hedges: Cross-currency contracts $ 2,875 $ 2,000 $ 43 $ — Foreign currency denominated debt 3,524 3,524 (36) — Cash flow hedges: Cross-currency contracts 4,000 4,000 192 35 Interest rate swaps 850 — — 1 Total $ 11,249 $ 9,524 $ 199 $ 36 For the Six-Month Period Ended July 1, 2022: Net investment hedges: Cross-currency contracts $ 3,875 $ 3,000 $ 267 $ — Foreign currency denominated debt 5,870 5,870 395 — Cash flow hedges: Cross-currency contracts 4,000 4,000 506 (340) Interest rate swaps 1,600 — — 2 Total $ 15,345 $ 12,870 $ 1,168 $ (338) For the Six-Month Period Ended July 2, 2021 Net investment hedges: Cross-currency contracts $ 2,875 $ 2,000 $ 66 $ — Foreign currency denominated debt 3,524 3,524 184 — Cash flow hedges: Cross-currency contracts 4,000 4,000 302 (117) Interest rate swaps 850 — — 1 Total $ 11,249 $ 9,524 $ 552 $ (116) Gains or losses related to net investment hedges are classified as foreign currency translation adjustments in the schedule of changes in OCI in Note 15, as these items are attributable to the Company’s hedges of its net investment in foreign operations. Gains or losses related to the cash flow hedges are classified as cash flow hedge adjustments in the schedule of changes in OCI in Note 15. The amounts reclassified from other comprehensive income (loss) for the cross-currency swap derivative contracts that are cash flow hedges of the Company’s U.S. dollar-denominated debt was equal to the remeasurement amount recorded in the three and six-month periods on the hedged debt. The Company did not reclassify any other deferred gains or losses related to net investment hedges or cash flow hedges from accumulated other comprehensive income (loss) to earnings during the three and six-month periods ended July 1, 2022 and July 2, 2021. In addition, the Company did not have any ineffectiveness related to net investment hedges or cash flow hedges during the three and six-month periods ended July 1, 2022 and July 2, 2021. The cash inflows and outflows associated with the Company’s derivative contracts designated as net investment hedges are classified in all other investing activities in the accompanying Consolidated Condensed Statements of Cash Flows. The cash inflows and outflows associated with the Company’s derivative contracts designated as cash flow hedges are classified in cash flows from operating activities in the accompanying Consolidated Condensed Statements of Cash Flows. The Company’s derivative instruments, as well as its nonderivative debt instruments designated and qualifying as net investment hedges, were classified in the Company’s Consolidated Condensed Balance Sheets as follows ($ in millions): July 1, 2022 December 31, 2021 Derivative assets: Other long-term assets $ 823 $ 50 Nonderivative hedging instruments: Long-term debt 5,870 3,883 Amounts related to the Company’s derivatives expected to be reclassified from accumulated other comprehensive income (loss) to net earnings during the next 12 months, if interest rates and foreign exchange rates remain unchanged, are not significant.

Defined Benefit Plans

Defined Benefit Plans	6 Months Ended
	Jul. 01, 2022
Retirement Benefits [Abstract]
Defined Benefit Plans	DEFINED BENEFIT PLANS The following sets forth the components of the Company’s net periodic benefit costs of the noncontributory defined benefit pension plans and other postretirement employee benefit plans ($ in millions): Three-Month Period Ended Six-Month Period Ended July 1, 2022 July 2, 2021 July 1, 2022 July 2, 2021 U.S. pension benefits: Service cost $ — $ — $ — $ — Interest cost (14) (11) (27) (23) Expected return on plan assets 33 31 65 62 Amortization of actuarial loss (9) (11) (18) (22) Net periodic pension benefit $ 10 $ 9 $ 20 $ 17 Non-U.S. pension benefits: Service cost $ (9) $ (11) $ (19) $ (22) Interest cost (6) (5) (12) (10) Expected return on plan assets 8 11 18 22 Amortization of actuarial loss (1) (3) (1) (6) Settlement losses recognized — — (10) — Net periodic pension cost $ (8) $ (8) $ (24) $ (16) Other postretirement employee benefit plans: Service cost $ — $ — $ — $ — Interest cost — — (1) (1) Amortization of actuarial loss — (1) — (1) Amortization of prior service credit — — 1 1 Net periodic benefit cost $ — $ (1) $ — $ (1) The service cost component of net periodic benefit costs is presented in cost of goods sold and selling, general and administrative expenses while the other cost components are presented in other income (expense), net. The Company’s net periodic pension cost for the six-month period ended July 1, 2022 includes a settlement loss of $10 million as a result of the transfer of a portion of its non-U.S. pension liabilities related to one defined benefit plan to a third-party. Employer Contributions

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jul. 01, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIES The Company reviews the adequacy of its legal reserves on a quarterly basis and establishes reserves for loss contingencies that are both probable and reasonably estimable. For a further description of the Company’s litigation and contingencies, refer to Note 18 of the Company’s financial statements as of and for the year ended December 31, 2021 included in the Company’s 2021 Annual Report. The Company generally accrues estimated warranty costs at the time of sale. In general, manufactured products are warranted against defects in material and workmanship when properly used for their intended purpose, installed correctly and appropriately maintained. Warranty periods depend on the nature of the product and range from the date of such sale up to ten years. The amount of the accrued warranty liability is determined based on historical information such as past experience, product failure rates or number of units repaired, estimated cost of material and labor and in certain instances estimated property damage. As of July 1, 2022 and December 31, 2021, the Company had accrued warranty liabilities of $87 million and $97 million, respectively.

Stockholders' Equity and Stock-

Stockholders' Equity and Stock-based Compensation	6 Months Ended
	Jul. 01, 2022
Share-Based Payment Arrangement [Abstract]
Stockholders' Equity and Stock-based Compensation	STOCKHOLDERS' EQUITY AND STOCK-BASED COMPENSATION Stockholders’ Equity Neither the Company nor any “affiliated purchaser” repurchased any shares of Company common stock during the six-month period ended July 1, 2022. On July 16, 2013, the Company’s Board of Directors approved a repurchase program (the “Repurchase Program”) authorizing the repurchase of up to 20 million shares of the Company’s common stock from time to time on the open market or in privately negotiated transactions. As of July 1, 2022 , 20 million shares rema ined available for repurchase pursuant to the Repurchase Program. The following table summarizes the Company’s share activity (shares in millions): Three-Month Period Ended Six-Month Period Ended July 1, 2022 July 2, 2021 July 1, 2022 July 2, 2021 Preferred stock - shares issued: Balance, beginning of period 3.4 3.4 3.4 3.4 Conversion of MCPS to common stock (1.7) — (1.7) — Balance, end of period 1.7 3.4 1.7 3.4 Common stock - shares issued: Balance, beginning of period 857.0 853.7 855.7 851.3 Common stock-based compensation awards 0.4 0.7 1.7 2.2 Common stock issued in connection with Liquid Yield Option Notes (“LYONs”) conversions — — — 0.9 Conversion of MCPS to common stock 11.0 — 11.0 — Balance, end of period 868.4 854.4 868.4 854.4 On April 15, 2022, all outstanding shares of the Company’s 4.75% MCPS Series A converted to common shares at a rate of 6.6632 common shares per share of preferred stock into an aggregate of 11.0 million shares of the Company’s common stock, pursuant to the terms of the Certificate of Designation governing the Series A Preferred Stock. Danaher issued cash in lieu of fractional shares of common stock in the conversion. The final quarterly cash dividend of $11.875 per share was paid on April 15, 2022. Unless converted earlier in accordance with the terms of the applicable certificate of designations, each share of MCPS Series B mandatorily converts on April 15, 2023 (the Mandatory Conversion Date) into a number of shares of the Company’s common stock between the Minimum Conversion Rate of 5.0130 shares and the Maximum Conversion Rate of 6.1409 shares (subject to further anti-dilution adjustments). The number of shares of the Company’s common stock issued and issuable upon conversion is determined based on the average volume-weighted average price per share of the Company’s common stock over the 20 consecutive trading day period beginning on, and including, the 21st scheduled trading day immediately before the Mandatory Conversion Date. Subject to certain exceptions, at any time prior to the Mandatory Conversion Date, holders may elect to convert the MCP S Series B shares into common stock based on the Minimum Conversion Rate (subject to further anti-dilution adjustments). In the event of a fundamental change, the MCPS Series B shares will convert at the fundamental change rates specified in the applicable certificate of designations, and the holders of MCPS Shares would be entitled to a fundamental change make-whole dividend. Holders of MCPS Series B are entitled to receive, when and if declared by the Company’s Board of Directors, cumulative dividends at the Annual Cumulative Dividend Rate of 5.00% of the Liquidation Preference of $1,000 per share, payable in cash or, subject to certain limitations, by delivery of shares of the Company’s common stock or any combination of cash and shares of the Company’s common stock, at the Company’s election. If declared, dividends on the MCPS Series B shares are payable quarterly on January 15, April 15, July 15 and October 15 of each year (to, and including, the Mandatory Conversion Date), to the holders of record of the MCPS Series B shares as they appear on the Company’s stock register at the close of business on the immediately preceding December 31, March 31, June 30 and September 30, respectively. Stock-Based Compensation For a full description of the Company’s stock-based compensation programs, refer to Note 19 of the Company’s financial statements as of and for the year ended December 31, 2021 included in the Company’s 2021 Annual Report. As of July 1, 2022, approxim ately 44 million shares of th e Company’s common stock were reserved for issuance under the 2007 Omnibus Incentive Plan. The following summarizes the components of the Company’s stock-based compensation expense ($ in millions): Three-Month Period Ended Six-Month Period Ended July 1, 2022 July 2, 2021 July 1, 2022 July 2, 2021 Restricted stock units (“RSUs”)/performance stock units (“PSUs”): Pretax compensation expense $ 58 $ 31 $ 104 $ 64 Income tax benefit (12) (6) (21) (13) RSU/PSU expense, net of income taxes 46 25 83 51 Stock options: Pretax compensation expense 43 22 77 43 Income tax benefit (9) (5) (16) (9) Stock option expense, net of income taxes 34 17 61 34 Total stock-based compensation: Pretax compensation expense 101 53 181 107 Income tax benefit (21) (11) (37) (22) Total stock-based compensation expense, net of income taxes $ 80 $ 42 $ 144 $ 85 Stock-based compensation has been recognized as a component of selling, general and administrative expenses in the accompanying Consolidated Condensed Statements of Earnings. As of July 1, 2022, $292 million of total unrecognized compensation cost related to RSUs/PSUs is expected to be recognized over a weighted average period of approximately two years. As of July 1, 2022, $300 million of total unrecognized compensation cost related to stock options is expected to be recognized over a weighted average period of approximately two years. Future compensation amounts will be adjusted for any changes in estimated forfeitures. Accumulated Other Comprehensive Income Accumulated other comprehensive income (loss) refers to certain gains and losses that under U.S. GAAP are included in comprehensive income (loss) but are excluded from net earnings as these amounts are initially recorded as an adjustment to stockholders’ equity. Foreign currency translation adjustments generally relate to indefinite investments in non-U.S. subsidiaries, as well as the impact from the Company’s hedges of its net investment in foreign operations, including the Company’s cross-currency swap derivatives, net of any income tax impacts. The changes in accumulated other comprehensive income (loss) by component are summarized below ($ in millions). Foreign Currency Translation Adjustments Pension and Postretirement Plan Benefit Adjustments Cash Flow Hedge Adjustments Accumulated Comprehensive Income (Loss) For the Three-Month Period Ended July 1, 2022: Balance, April 1, 2022 $ (882) $ (536) $ 42 $ (1,376) Other comprehensive income (loss) before reclassifications: (Decrease) increase (1,390) — 381 (1,009) Income tax impact (52) — (92) (144) Other comprehensive income (loss) before reclassifications, net of income taxes (1,442) — 289 (1,153) Reclassification adjustments: Increase (decrease) — 10 (a) (223) (b) (213) Income tax impact — (3) — (3) Reclassification adjustments, net of income taxes — 7 (223) (216) Net other comprehensive income (loss), net of income taxes (1,442) 7 66 (1,369) Balance, July 1, 2022 $ (2,324) $ (529) $ 108 $ (2,745) For the Three-Month Period Ended July 2, 2021: Balance, April 2, 2021 $ (177) $ (918) $ (227) $ (1,322) Other comprehensive income (loss) before reclassifications: Increase 418 — 192 610 Income tax impact (10) — — (10) Other comprehensive income (loss) before reclassifications, net of income taxes 408 — 192 600 Reclassification adjustments: Increase — 15 (a) 36 (b) 51 Income tax impact — (4) — (4) Reclassification adjustments, net of income taxes — 11 36 47 Net other comprehensive income (loss), net of income taxes 408 11 228 647 Balance, July 2, 2021 $ 231 $ (907) $ 1 $ (675) Foreign Currency Translation Adjustments Pension and Postretirement Plan Benefit Adjustments Cash Flow Hedge Adjustments Accumulated Comprehensive Income (Loss) For the Six-Month Period Ended July 1, 2022: Balance, December 31, 2021 $ (539) $ (550) $ 62 $ (1,027) Other comprehensive income (loss) before reclassifications: (Decrease) increase (1,721) — 506 (1,215) Income tax impact (64) — (122) (186) Other comprehensive income (loss) before reclassifications, net of income taxes (1,785) — 384 (1,401) Reclassification adjustments: Increase (decrease) — 28 (a) (338) (b) (310) Income tax impact — (7) — (7) Reclassification adjustments, net of income taxes — 21 (338) (317) Net other comprehensive income (loss), net of income taxes (1,785) 21 46 (1,718) Balance, July 1, 2022 $ (2,324) $ (529) $ 108 $ (2,745) For the Six-Month Period Ended July 2, 2021: Balance, December 31, 2020 $ 745 $ (928) $ (185) $ (368) Other comprehensive income (loss) before reclassifications: (Decrease) increase (499) — 302 (197) Income tax impact (15) — — (15) Other comprehensive income (loss) before reclassifications, net of income taxes (514) — 302 (212) Reclassification adjustments: Increase (decrease) — 28 (a) (116) (b) (88) Income tax impact — (7) — (7) Reclassification adjustments, net of income taxes — 21 (116) (95) Net other comprehensive income (loss), net of income taxes (514) 21 186 (307) Balance, July 2, 2021 $ 231 $ (907) $ 1 $ (675) (a) This accumulated other comprehensive income (loss) component is included in the computation of net periodic benefit cost (refer to Notes 8 and 13 for additional details). (b) Reflects reclassification to earnings related to cash flow hedges of certain long-term debt (refer to Note 12 for additional details).

General (Policies)

General (Policies)	6 Months Ended
	Jul. 01, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accounting Standards Recently Adopted	Accounting Standards Recently Adopted —In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The ASU includes amendments to the guidance on convertible instruments and the derivative scope exception for contracts in an entity’s own equity and simplifies the accounting for convertible instruments which include beneficial conversion features or cash conversion features by removing certain separation models in Subtopic 470-20. Additionally, the ASU requires entities to use the “if-converted” method when calculating diluted earnings per common share for convertible instruments. On January 1, 2022, the Company adopted the ASU and the ASU did not have a significant impact on the Company’s financial statements. In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832) , which requires annual disclosures of transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. For the Company, these disclosures will initially be required for the Company’s financial statements for the year ending December 31, 2022. These required annual disclosures include information on the nature of transactions and related accounting policies used to account for transactions, detail of the line items on the balance sheet and income statement affected by these transactions, including amounts applicable to each line, and significant terms and conditions of the transactions including commitments and contingencies. On January 1, 2022, the Company adopted the ASU. The Company is in the process of assessing the impact of this ASU and drafting the annual disclosures. In June 2022, the FASB issued ASU No. 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions . The ASU clarifies the guidance in ASC 820, Fair Value Measurement, related to the measurement of the fair value of an equity security subject to contractual sale restrictions and introduces disclosure requirements related to such equity securities. The Company early adopted the ASU effective July 1, 2022. The impact of the adoption of the ASU was not significant.
Operating Leases	Operating Leases —As of both July 1, 2022 and December 31, 2021, operating lease right-of-use assets where the Company was the lessee were approximately $1.0 billion and are included within other long-term assets in the accompanying Consolidated Condensed Balance Sheets. The associated operating lease liabilities were approximately $1.1 billion as of both July 1, 2022 and December 31, 2021 and are included in accrued expenses and other liabilities and other long-term liabilities.

Acquisitions (Tables)

Acquisitions (Tables)	6 Months Ended
	Jul. 01, 2022
Business Combination and Asset Acquisition [Abstract]
Fair Values of the Assets Acquired and Liabilities Assumed	The following summarizes the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition for the six-month period ended July 1, 2022 ($ in millions): Goodwill $ 44 Other intangible assets, primarily technology and customer relationships 35 Deferred tax liabilities (4) Other assets and liabilities, net 2 Net cash consideration $ 77
Pro Forma Financial Information	The pro forma information is presented for informational purposes only and is not necessarily indicative of the results of operations that actually would have been achieved had the acquisitions been consummated as of that time ( $ in millions, except per share amounts): Three-Month Period Ended Six-Month Period Ended July 1, 2022 July 2, 2021 July 1, 2022 July 2, 2021 Sales $ 7,751 $ 7,320 $ 15,440 $ 14,287 Net earnings from continuing operations 1,679 1,638 3,404 3,265 Diluted net earnings per common share from continuing operations (a) 2.25 2.20 4.56 4.38 (a) Diluted net earnings per common share from continuing operations is calculated by deducting the Mandatory Convertible Preferred Stock (“MCPS”) dividends from net earnings from continuing operations for the anti-dilutive MCPS shares (refer to Note 4 for additional information).

Net Earnings Per Common Share (

Net Earnings Per Common Share (Tables)	6 Months Ended
	Jul. 01, 2022
Earnings Per Share [Abstract]
Information Related to the Calculation of Net Earnings Per Common Share	Information related to the calculation of net earnings per common share from continuing operations is summarized as follows ($ and shares in millions, except per share amounts): Three-Month Period Ended Six-Month Period Ended July 1, 2022 July 2, 2021 July 1, 2022 July 2, 2021 Numerator: Net earnings from continuing operations $ 1,680 $ 1,699 $ 3,405 $ 3,401 MCPS dividends (22) (41) (63) (82) Net earnings from continuing operations attributable to common stockholders for Basic EPS 1,658 1,658 3,342 3,319 Adjustment for MCPS dividends for dilutive MCPS — 20 20 40 Net earnings from continuing operations attributable to common stockholders after assumed conversions for Diluted EPS $ 1,658 $ 1,678 $ 3,362 $ 3,359 Denominator: Weighted average common shares outstanding used in Basic EPS 726.7 714.5 721.5 713.9 Incremental common shares from: Assumed exercise of dilutive options and vesting of dilutive RSUs and PSUs 8.2 10.5 9.3 10.6 Assumed conversion of the convertible debentures — — — 0.1 Weighted average MCPS converted shares 1.1 11.0 6.0 11.0 Weighted average common shares outstanding used in Diluted EPS 736.0 736.0 736.8 735.6 Basic EPS from continuing operations $ 2.28 $ 2.32 $ 4.63 $ 4.65 Diluted EPS from continuing operations $ 2.25 $ 2.28 $ 4.56 $ 4.57

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Jul. 01, 2022
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following tables present the Company’s revenues disaggregated by geographical region and revenue type for the three and six-month periods ended July 1, 2022 and July 2, 2021 ($ in millions) . Sales taxes and other usage-based taxes collected from customers are excluded from revenue. Life Sciences Diagnostics Environmental & Applied Solutions Total For the Three-Month Period Ended July 1, 2022: Geographical region: North America (b) $ 1,576 $ 1,235 $ 571 $ 3,382 Western Europe 972 453 266 1,691 Other developed markets 199 115 32 346 High-growth markets (a) 1,220 758 354 2,332 Total $ 3,967 $ 2,561 $ 1,223 $ 7,751 Revenue type: Recurring $ 2,872 $ 2,301 $ 719 $ 5,892 Nonrecurring 1,095 260 504 1,859 Total $ 3,967 $ 2,561 $ 1,223 $ 7,751 For the Three-Month Period Ended July 2, 2021: Geographical region: North America (b) $ 1,349 $ 970 $ 497 $ 2,816 Western Europe 1,052 443 275 1,770 Other developed markets 209 111 30 350 High-growth markets (a) 1,124 812 346 2,282 Total $ 3,734 $ 2,336 $ 1,148 $ 7,218 Revenue type: Recurring $ 2,640 $ 2,022 $ 658 $ 5,320 Nonrecurring 1,094 314 490 1,898 Total $ 3,734 $ 2,336 $ 1,148 $ 7,218 Life Sciences Diagnostics Environmental & Applied Solutions Total For the Six-Month Period Ended July 1, 2022: Geographical region: North America (b) $ 3,096 $ 2,541 $ 1,099 $ 6,736 Western Europe 2,007 977 535 3,519 Other developed markets 421 239 64 724 High-growth markets (a) 2,325 1,448 687 4,460 Total $ 7,849 $ 5,205 $ 2,385 $ 15,439 Revenue type: Recurring $ 5,710 $ 4,671 $ 1,409 $ 11,790 Nonrecurring 2,139 534 976 3,649 Total $ 7,849 $ 5,205 $ 2,385 $ 15,439 For the Six-Month Period Ended July 2, 2021: Geographical region: North America (b) $ 2,612 $ 1,942 $ 989 $ 5,543 Western Europe 2,022 858 554 3,434 Other developed markets 434 229 59 722 High-growth markets (a) 2,212 1,485 680 4,377 Total $ 7,280 $ 4,514 $ 2,282 $ 14,076 Revenue type: Recurring $ 5,169 $ 3,924 $ 1,306 $ 10,399 Nonrecurring 2,111 590 976 3,677 Total $ 7,280 $ 4,514 $ 2,282 $ 14,076 (a) The Company defines high-growth markets as developing markets of the world experiencing extended periods of accelerated growth in gross domestic product and infrastructure which include Eastern Europe, the Middle East, Africa, Latin America and Asia (with the exception of Japan, Australia and New Zealand). The Company defines developed markets as all markets that are not high-growth markets. (b ) The Company defines North America as the United States and Canada.

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Jul. 01, 2022
Segment Reporting [Abstract]
Segment Results	Segment results are shown below ($ in millions): Three-Month Period Ended Six-Month Period Ended July 1, 2022 July 2, 2021 July 1, 2022 July 2, 2021 Sales: Life Sciences $ 3,967 $ 3,734 $ 7,849 $ 7,280 Diagnostics 2,561 2,336 5,205 4,514 Environmental & Applied Solutions 1,223 1,148 2,385 2,282 Total $ 7,751 $ 7,218 $ 15,439 $ 14,076 Operating profit: Life Sciences $ 1,174 $ 1,144 $ 2,292 $ 2,295 Diagnostics 800 649 1,686 1,275 Environmental & Applied Solutions 307 280 543 565 Other (76) (68) (144) (133) Total $ 2,205 $ 2,005 $ 4,377 $ 4,002

Income Taxes (Tables)

Income Taxes (Tables)	6 Months Ended
	Jul. 01, 2022
Income Tax Disclosure [Abstract]
Summary of Effective Income Tax Rate	The following table summarizes the Company’s effective tax rate: Three-Month Period Ended Six-Month Period Ended July 1, 2022 July 2, 2021 July 1, 2022 July 2, 2021 Effective tax rate 18.8 % 16.8 % 18.3 % 17.6 %

Other Income (Expense), Net (Ta

Other Income (Expense), Net (Tables)	6 Months Ended
	Jul. 01, 2022
Other Income and Expenses [Abstract]
Schedule of Other Nonoperating Income (Expense)	The following sets forth the components of the Company’s other income (expense), net ($ in millions): Three-Month Period Ended Six-Month Period Ended July 1, 2022 July 2, 2021 July 1, 2022 July 2, 2021 Other components of net periodic benefit costs $ 11 $ 11 $ 15 $ 22 Investment gains (losses): Realized investment gains (losses) 27 11 64 38 Unrealized investment gains (losses) (125) 75 (186) 164 Total investment gains (losses) (98) 86 (122) 202 Gain on sale of product lines — — — 13 Total other income (expense), net $ (87) $ 97 $ (107) $ 237

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets (Tables)	6 Months Ended
	Jul. 01, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Rollforward of Goodwill	The following is a rollforward of the Company’s goodwill ($ in millions): Balance, December 31, 2021 $ 41,184 Attributable to 2022 acquisitions 44 Adjustments due to finalization of purchase price allocations (15) Foreign currency translation and other (1,937) Balance, July 1, 2022 $ 39,276 The carrying value of goodwill by segment is summarized as follows ($ in millions): July 1, 2022 December 31, 2021 Life Sciences $ 30,003 $ 31,638 Diagnostics 6,843 7,044 Environmental & Applied Solutions 2,430 2,502 Total $ 39,276 $ 41,184
Goodwill by Segment	The following is a rollforward of the Company’s goodwill ($ in millions): Balance, December 31, 2021 $ 41,184 Attributable to 2022 acquisitions 44 Adjustments due to finalization of purchase price allocations (15) Foreign currency translation and other (1,937) Balance, July 1, 2022 $ 39,276 The carrying value of goodwill by segment is summarized as follows ($ in millions): July 1, 2022 December 31, 2021 Life Sciences $ 30,003 $ 31,638 Diagnostics 6,843 7,044 Environmental & Applied Solutions 2,430 2,502 Total $ 39,276 $ 41,184

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jul. 01, 2022
Fair Value Disclosures [Abstract]
Financial Assets and Liabilities Carried at Fair Value	A summary of financial assets and liabilities that are measured at fair value on a recurring basis were as follows ($ in millions): Balance Quoted Prices in Active Market (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) July 1, 2022 December 31, 2021 July 1, 2022 December 31, 2021 July 1, 2022 December 31, 2021 July 1, 2022 December 31, 2021 Assets: Available-for-sale debt securities $ 15 $ 20 $ — $ — $ 15 $ 20 $ — $ — Investment in equity securities 316 336 26 88 — — — — Cross-currency swap derivative contracts 823 50 — — 823 50 — —
Carrying Amounts and Fair Values of Financial Instruments	The carrying amounts and fair values of the Company’s other financial instruments were as follows ($ in millions): July 1, 2022 December 31, 2021 Carrying Amount Fair Value Carrying Amount Fair Value Debt obligations: Notes payable and current portion of long-term debt $ 10 $ 10 $ 8 $ 8 Long-term debt 20,052 17,706 22,168 22,796

Financing (Tables)

Financing (Tables)	6 Months Ended
	Jul. 01, 2022
Debt Disclosure [Abstract]
Components of Debt	The components of the Company’s debt were as follows ($ in millions): Description and Aggregate Principal Amount July 1, 2022 December 31, 2021 U.S. dollar-denominated commercial paper $ — $ 1,440 Euro-denominated commercial paper (€1.9 billion and €1.2 billion, respectively) 2,008 1,366 Floating rate senior unsecured notes due 6/30/2022 (€250 million) (the “Floating Rate 2022 Euronotes”) — 284 2.05% senior unsecured notes due 11/15/2022 (the “2022 Biopharma Notes”) 700 699 0.5% senior unsecured bonds due 12/08/2023 (CHF 540 million) (the “2023 CHF Bonds”) 563 592 1.7% senior unsecured notes due 3/30/2024 (€900 million) (the “2024 Euronotes”) 936 1,021 2.2% senior unsecured notes due 11/15/2024 (the “2024 Biopharma Notes”) 698 698 3.35% senior unsecured notes due 9/15/2025 (the “2025 U.S. Notes”) 498 498 0.2% senior unsecured notes due 3/18/2026 (€1.3 billion) (the “2026 Biopharma Euronotes”) 1,298 1,416 2.1% senior unsecured notes due 9/30/2026 (€800 million) (the “2026 Euronotes”) 832 907 0.3% senior unsecured notes due 5/11/2027 (¥30.8 billion) (the “2027 Yen Notes”) 227 267 1.2% senior unsecured notes due 6/30/2027 (€600 million) (the “2027 Euronotes”) 624 680 0.45% senior unsecured notes due 3/18/2028 (€1.3 billion) (the “2028 Biopharma Euronotes”) 1,296 1,413 1.125% senior unsecured bonds due 12/08/2028 (CHF 210 million) (the “2028 CHF Bonds”) 222 233 2.6% senior unsecured notes due 11/15/2029 (the “2029 Biopharma Notes”) 796 795 2.5% senior unsecured notes due 3/30/2030 (€800 million) (the “2030 Euronotes”) 834 910 0.75% senior unsecured notes due 9/18/2031 (€1.8 billion) (the “2031 Biopharma Euronotes”) 1,814 1,980 0.65% senior unsecured notes due 5/11/2032 (¥53.2 billion) (the “2032 Yen Notes”) 392 461 1.35% senior unsecured notes due 9/18/2039 (€1.3 billion) (the “2039 Biopharma Euronotes”) 1,288 1,406 3.25% senior unsecured notes due 11/15/2039 (the “2039 Biopharma Notes”) 890 890 4.375% senior unsecured notes due 9/15/2045 (the “2045 U.S. Notes”) 499 499 1.8% senior unsecured notes due 9/18/2049 (€750 million) (the “2049 Biopharma Euronotes”) 773 844 3.4% senior unsecured notes due 11/15/2049 (the “2049 Biopharma Notes”) 889 889 2.6% senior unsecured notes due 10/01/2050 (the “2050 U.S. Notes”) 980 980 2.8% senior unsecured notes due 12/10/2051 (the “2051 U.S. Notes”) 984 983 Other 21 25 Total debt 20,062 22,176 Less: currently payable (10) (8) Long-term debt $ 20,052 $ 22,168

Hedging Transactions and Deri_2

Hedging Transactions and Derivative Financial Instruments (Tables)	6 Months Ended
	Jul. 01, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments, Gain (Loss)	The following table summarizes the notional values as of July 1, 2022 and July 2, 2021 and pretax impact of changes in the fair values of instruments designated as net investment hedges and cash flow hedges in accumulated other comprehensive income (“OCI”) for the three and six-month periods ended July 1, 2022 and July 2, 2021 ($ in millions): Original Notional Amount Notional Amount Outstanding Gain (Loss) Recognized in OCI Amounts Reclassified from OCI For the Three-Month Period Ended July 1, 2022: Net investment hedges: Cross-currency contracts $ 3,875 $ 3,000 $ 216 $ — Foreign currency denominated debt 5,870 5,870 271 — Cash flow hedges: Cross-currency contracts 4,000 4,000 381 (224) Interest rate swaps 1,600 — — 1 Total $ 15,345 $ 12,870 $ 868 $ (223) For the Three-Month Period Ended July 2, 2021: Net investment hedges: Cross-currency contracts $ 2,875 $ 2,000 $ 43 $ — Foreign currency denominated debt 3,524 3,524 (36) — Cash flow hedges: Cross-currency contracts 4,000 4,000 192 35 Interest rate swaps 850 — — 1 Total $ 11,249 $ 9,524 $ 199 $ 36 For the Six-Month Period Ended July 1, 2022: Net investment hedges: Cross-currency contracts $ 3,875 $ 3,000 $ 267 $ — Foreign currency denominated debt 5,870 5,870 395 — Cash flow hedges: Cross-currency contracts 4,000 4,000 506 (340) Interest rate swaps 1,600 — — 2 Total $ 15,345 $ 12,870 $ 1,168 $ (338) For the Six-Month Period Ended July 2, 2021 Net investment hedges: Cross-currency contracts $ 2,875 $ 2,000 $ 66 $ — Foreign currency denominated debt 3,524 3,524 184 — Cash flow hedges: Cross-currency contracts 4,000 4,000 302 (117) Interest rate swaps 850 — — 1 Total $ 11,249 $ 9,524 $ 552 $ (116)
Schedule of Notional Amounts of Outstanding Derivative Positions	The following table summarizes the notional values as of July 1, 2022 and July 2, 2021 and pretax impact of changes in the fair values of instruments designated as net investment hedges and cash flow hedges in accumulated other comprehensive income (“OCI”) for the three and six-month periods ended July 1, 2022 and July 2, 2021 ($ in millions): Original Notional Amount Notional Amount Outstanding Gain (Loss) Recognized in OCI Amounts Reclassified from OCI For the Three-Month Period Ended July 1, 2022: Net investment hedges: Cross-currency contracts $ 3,875 $ 3,000 $ 216 $ — Foreign currency denominated debt 5,870 5,870 271 — Cash flow hedges: Cross-currency contracts 4,000 4,000 381 (224) Interest rate swaps 1,600 — — 1 Total $ 15,345 $ 12,870 $ 868 $ (223) For the Three-Month Period Ended July 2, 2021: Net investment hedges: Cross-currency contracts $ 2,875 $ 2,000 $ 43 $ — Foreign currency denominated debt 3,524 3,524 (36) — Cash flow hedges: Cross-currency contracts 4,000 4,000 192 35 Interest rate swaps 850 — — 1 Total $ 11,249 $ 9,524 $ 199 $ 36 For the Six-Month Period Ended July 1, 2022: Net investment hedges: Cross-currency contracts $ 3,875 $ 3,000 $ 267 $ — Foreign currency denominated debt 5,870 5,870 395 — Cash flow hedges: Cross-currency contracts 4,000 4,000 506 (340) Interest rate swaps 1,600 — — 2 Total $ 15,345 $ 12,870 $ 1,168 $ (338) For the Six-Month Period Ended July 2, 2021 Net investment hedges: Cross-currency contracts $ 2,875 $ 2,000 $ 66 $ — Foreign currency denominated debt 3,524 3,524 184 — Cash flow hedges: Cross-currency contracts 4,000 4,000 302 (117) Interest rate swaps 850 — — 1 Total $ 11,249 $ 9,524 $ 552 $ (116)
Schedule of Derivative and Non Derivative Instruments in Consolidated Condensed Balance Sheets	The Company’s derivative instruments, as well as its nonderivative debt instruments designated and qualifying as net investment hedges, were classified in the Company’s Consolidated Condensed Balance Sheets as follows ($ in millions): July 1, 2022 December 31, 2021 Derivative assets: Other long-term assets $ 823 $ 50 Nonderivative hedging instruments: Long-term debt 5,870 3,883

Defined Benefit Plans (Tables)

Defined Benefit Plans (Tables)	6 Months Ended
	Jul. 01, 2022
Retirement Benefits [Abstract]
Schedule of Net Benefit Costs	The following sets forth the components of the Company’s net periodic benefit costs of the noncontributory defined benefit pension plans and other postretirement employee benefit plans ($ in millions): Three-Month Period Ended Six-Month Period Ended July 1, 2022 July 2, 2021 July 1, 2022 July 2, 2021 U.S. pension benefits: Service cost $ — $ — $ — $ — Interest cost (14) (11) (27) (23) Expected return on plan assets 33 31 65 62 Amortization of actuarial loss (9) (11) (18) (22) Net periodic pension benefit $ 10 $ 9 $ 20 $ 17 Non-U.S. pension benefits: Service cost $ (9) $ (11) $ (19) $ (22) Interest cost (6) (5) (12) (10) Expected return on plan assets 8 11 18 22 Amortization of actuarial loss (1) (3) (1) (6) Settlement losses recognized — — (10) — Net periodic pension cost $ (8) $ (8) $ (24) $ (16) Other postretirement employee benefit plans: Service cost $ — $ — $ — $ — Interest cost — — (1) (1) Amortization of actuarial loss — (1) — (1) Amortization of prior service credit — — 1 1 Net periodic benefit cost $ — $ (1) $ — $ (1)

Stockholders' Equity and Stoc_2

Stockholders' Equity and Stock-based Compensation (Tables)	6 Months Ended
	Jul. 01, 2022
Share-Based Payment Arrangement [Abstract]
Summary of Share Activity	The following table summarizes the Company’s share activity (shares in millions): Three-Month Period Ended Six-Month Period Ended July 1, 2022 July 2, 2021 July 1, 2022 July 2, 2021 Preferred stock - shares issued: Balance, beginning of period 3.4 3.4 3.4 3.4 Conversion of MCPS to common stock (1.7) — (1.7) — Balance, end of period 1.7 3.4 1.7 3.4 Common stock - shares issued: Balance, beginning of period 857.0 853.7 855.7 851.3 Common stock-based compensation awards 0.4 0.7 1.7 2.2 Common stock issued in connection with Liquid Yield Option Notes (“LYONs”) conversions — — — 0.9 Conversion of MCPS to common stock 11.0 — 11.0 — Balance, end of period 868.4 854.4 868.4 854.4
Components of Stock-Based Compensation Program	The following summarizes the components of the Company’s stock-based compensation expense ($ in millions): Three-Month Period Ended Six-Month Period Ended July 1, 2022 July 2, 2021 July 1, 2022 July 2, 2021 Restricted stock units (“RSUs”)/performance stock units (“PSUs”): Pretax compensation expense $ 58 $ 31 $ 104 $ 64 Income tax benefit (12) (6) (21) (13) RSU/PSU expense, net of income taxes 46 25 83 51 Stock options: Pretax compensation expense 43 22 77 43 Income tax benefit (9) (5) (16) (9) Stock option expense, net of income taxes 34 17 61 34 Total stock-based compensation: Pretax compensation expense 101 53 181 107 Income tax benefit (21) (11) (37) (22) Total stock-based compensation expense, net of income taxes $ 80 $ 42 $ 144 $ 85
Components of Accumulated Other Comprehensive Income (Loss)	The changes in accumulated other comprehensive income (loss) by component are summarized below ($ in millions). Foreign Currency Translation Adjustments Pension and Postretirement Plan Benefit Adjustments Cash Flow Hedge Adjustments Accumulated Comprehensive Income (Loss) For the Three-Month Period Ended July 1, 2022: Balance, April 1, 2022 $ (882) $ (536) $ 42 $ (1,376) Other comprehensive income (loss) before reclassifications: (Decrease) increase (1,390) — 381 (1,009) Income tax impact (52) — (92) (144) Other comprehensive income (loss) before reclassifications, net of income taxes (1,442) — 289 (1,153) Reclassification adjustments: Increase (decrease) — 10 (a) (223) (b) (213) Income tax impact — (3) — (3) Reclassification adjustments, net of income taxes — 7 (223) (216) Net other comprehensive income (loss), net of income taxes (1,442) 7 66 (1,369) Balance, July 1, 2022 $ (2,324) $ (529) $ 108 $ (2,745) For the Three-Month Period Ended July 2, 2021: Balance, April 2, 2021 $ (177) $ (918) $ (227) $ (1,322) Other comprehensive income (loss) before reclassifications: Increase 418 — 192 610 Income tax impact (10) — — (10) Other comprehensive income (loss) before reclassifications, net of income taxes 408 — 192 600 Reclassification adjustments: Increase — 15 (a) 36 (b) 51 Income tax impact — (4) — (4) Reclassification adjustments, net of income taxes — 11 36 47 Net other comprehensive income (loss), net of income taxes 408 11 228 647 Balance, July 2, 2021 $ 231 $ (907) $ 1 $ (675) Foreign Currency Translation Adjustments Pension and Postretirement Plan Benefit Adjustments Cash Flow Hedge Adjustments Accumulated Comprehensive Income (Loss) For the Six-Month Period Ended July 1, 2022: Balance, December 31, 2021 $ (539) $ (550) $ 62 $ (1,027) Other comprehensive income (loss) before reclassifications: (Decrease) increase (1,721) — 506 (1,215) Income tax impact (64) — (122) (186) Other comprehensive income (loss) before reclassifications, net of income taxes (1,785) — 384 (1,401) Reclassification adjustments: Increase (decrease) — 28 (a) (338) (b) (310) Income tax impact — (7) — (7) Reclassification adjustments, net of income taxes — 21 (338) (317) Net other comprehensive income (loss), net of income taxes (1,785) 21 46 (1,718) Balance, July 1, 2022 $ (2,324) $ (529) $ 108 $ (2,745) For the Six-Month Period Ended July 2, 2021: Balance, December 31, 2020 $ 745 $ (928) $ (185) $ (368) Other comprehensive income (loss) before reclassifications: (Decrease) increase (499) — 302 (197) Income tax impact (15) — — (15) Other comprehensive income (loss) before reclassifications, net of income taxes (514) — 302 (212) Reclassification adjustments: Increase (decrease) — 28 (a) (116) (b) (88) Income tax impact — (7) — (7) Reclassification adjustments, net of income taxes — 21 (116) (95) Net other comprehensive income (loss), net of income taxes (514) 21 186 (307) Balance, July 2, 2021 $ 231 $ (907) $ 1 $ (675) (a) This accumulated other comprehensive income (loss) component is included in the computation of net periodic benefit cost (refer to Notes 8 and 13 for additional details). (b) Reflects reclassification to earnings related to cash flow hedges of certain long-term debt (refer to Note 12 for additional details).

General (Narrative) (Details)

General (Narrative) (Details) - USD ($) $ in Billions	Jul. 01, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Operating lease, right-of-use assets	$ 1	$ 1
Operating lease, liabilities	$ 1.1	$ 1.1

Acquisitions (Narrative) (Detai

Acquisitions (Narrative) (Details) $ in Millions	6 Months Ended
	Jul. 01, 2022 USD ($) Business	Jul. 02, 2021 USD ($)
Business Acquisition [Line Items]
Cash paid for acquisition	$ 77	$ 1,065
Series of individually immaterial business acquisitions
Business Acquisition [Line Items]
Number of businesses acquired | Business	2
Cash paid for acquisition	$ 77
Revenue reported by acquired entity for last annual period	$ 7

Acquisitions (Fair Values of th

Acquisitions (Fair Values of the Assets Acquired and Liabilities) (Details) - USD ($) $ in Millions	6 Months Ended
	Jul. 01, 2022	Jul. 02, 2021	Dec. 31, 2021
Business Acquisition [Line Items]
Goodwill	$ 39,276		$ 41,184
Cash paid for acquisition	77	$ 1,065
Series of individually immaterial business acquisitions
Business Acquisition [Line Items]
Goodwill	44
Other intangible assets, primarily technology and customer relationships	35
Deferred tax liabilities	(4)
Other assets and liabilities, net	2
Cash paid for acquisition	$ 77

Acquisitions (Pro Forma Financi

Acquisitions (Pro Forma Financial Information) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2022	Jul. 02, 2021	Jul. 01, 2022	Jul. 02, 2021
Business Combinations [Abstract]
Sales	$ 7,751	$ 7,320	$ 15,440	$ 14,287
Net earnings from continuing operations	$ 1,679	$ 1,638	$ 3,404	$ 3,265
Diluted net earnings per common share from continuing operations (in usd per share)	$ 2.25	$ 2.20	$ 4.56	$ 4.38

Discontinued Operations (Detail

Discontinued Operations (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jul. 02, 2021	Jul. 02, 2021
Discontinued Operations and Disposal Groups [Abstract]
Tax effect of discontinued operation	$ 86	$ 86

Net Earnings Per Common Share_2

Net Earnings Per Common Share (Narrative) (Details) - USD ($) shares in Thousands, $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2022	Jul. 02, 2021	Jul. 01, 2022	Jul. 02, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average MCPS converted shares (in shares)	1,100	11,000	6,000	11,000
Mandatory convertible preferred stock dividends	$ 22	$ 41	$ 63	$ 82
Preferred stock series A
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average MCPS converted shares (in shares)	1,100	11,000	6,000	11,000
Mandatory convertible preferred stock dividends	$ 0	$ 20	$ 20	$ 40
5.00% Mandatory Convertible Preferred Stock, Series B, without par value
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	8,600	8,600	8,600	8,600
Mandatory convertible preferred stock dividends	$ 22	$ 21	$ 43	$ 42
Common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	2,400	193	2,400	132

Net Earnings Per Common Share_3

Net Earnings Per Common Share (Components of Basic and Diluted Earnings per Share from Continuing Operations) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2022	Jul. 02, 2021	Jul. 01, 2022	Jul. 02, 2021
Numerator
Net earnings from continuing operations	$ 1,680	$ 1,699	$ 3,405	$ 3,401
MCPS dividends	(22)	(41)	(63)	(82)
Net earnings from continuing operations attributable to common stockholders for Basis EPS	1,658	1,658	3,342	3,319
Adjustment for MCPS dividends for dilutive MCPS	0	20	20	40
Net earnings from continuing operations attributable to common stockholders after assumed conversions for Diluted EPS	$ 1,658	$ 1,678	$ 3,362	$ 3,359
Denominator
Weighted average common shares outstanding used in Basic EPS (in shares)	726.7	714.5	721.5	713.9
Assumed exercise of dilutive options and vesting of dilutive RSUs and PSUs (in shares)	8.2	10.5	9.3	10.6
Assumed conversion of the convertible debentures (in shares)	0	0	0	0.1
Weighted average MCPS converted shares (in shares)	1.1	11	6	11
Weighted average common shares outstanding used in Diluted EPS (in shares)	736	736	736.8	735.6
Basic EPS from continuing operations (in usd per share)	$ 2.28	$ 2.32	$ 4.63	$ 4.65
Diluted EPS from continuing operations (in usd per share)	$ 2.25	$ 2.28	$ 4.56	$ 4.57

Revenue (Disaggregation of Reve

Revenue (Disaggregation of Revenue by Geographical Region) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2022	Jul. 02, 2021	Jul. 01, 2022	Jul. 02, 2021
Disaggregation of Revenue [Line Items]
Revenue	$ 7,751	$ 7,218	$ 15,439	$ 14,076
Recurring revenue
Disaggregation of Revenue [Line Items]
Revenue	5,892	5,320	11,790	10,399
Nonrecurring revenue
Disaggregation of Revenue [Line Items]
Revenue	1,859	1,898	3,649	3,677
North America
Disaggregation of Revenue [Line Items]
Revenue	3,382	2,816	6,736	5,543
Western Europe
Disaggregation of Revenue [Line Items]
Revenue	1,691	1,770	3,519	3,434
Other developed markets
Disaggregation of Revenue [Line Items]
Revenue	346	350	724	722
High-growth markets
Disaggregation of Revenue [Line Items]
Revenue	2,332	2,282	4,460	4,377
Operating segments | Life Sciences
Disaggregation of Revenue [Line Items]
Revenue	3,967	3,734	7,849	7,280
Operating segments | Life Sciences | Recurring revenue
Disaggregation of Revenue [Line Items]
Revenue	2,872	2,640	5,710	5,169
Operating segments | Life Sciences | Nonrecurring revenue
Disaggregation of Revenue [Line Items]
Revenue	1,095	1,094	2,139	2,111
Operating segments | Life Sciences | North America
Disaggregation of Revenue [Line Items]
Revenue	1,576	1,349	3,096	2,612
Operating segments | Life Sciences | Western Europe
Disaggregation of Revenue [Line Items]
Revenue	972	1,052	2,007	2,022
Operating segments | Life Sciences | Other developed markets
Disaggregation of Revenue [Line Items]
Revenue	199	209	421	434
Operating segments | Life Sciences | High-growth markets
Disaggregation of Revenue [Line Items]
Revenue	1,220	1,124	2,325	2,212
Operating segments | Diagnostics
Disaggregation of Revenue [Line Items]
Revenue	2,561	2,336	5,205	4,514
Operating segments | Diagnostics | Recurring revenue
Disaggregation of Revenue [Line Items]
Revenue	2,301	2,022	4,671	3,924
Operating segments | Diagnostics | Nonrecurring revenue
Disaggregation of Revenue [Line Items]
Revenue	260	314	534	590
Operating segments | Diagnostics | North America
Disaggregation of Revenue [Line Items]
Revenue	1,235	970	2,541	1,942
Operating segments | Diagnostics | Western Europe
Disaggregation of Revenue [Line Items]
Revenue	453	443	977	858
Operating segments | Diagnostics | Other developed markets
Disaggregation of Revenue [Line Items]
Revenue	115	111	239	229
Operating segments | Diagnostics | High-growth markets
Disaggregation of Revenue [Line Items]
Revenue	758	812	1,448	1,485
Operating segments | Environmental & Applied Solutions
Disaggregation of Revenue [Line Items]
Revenue	1,223	1,148	2,385	2,282
Operating segments | Environmental & Applied Solutions | Recurring revenue
Disaggregation of Revenue [Line Items]
Revenue	719	658	1,409	1,306
Operating segments | Environmental & Applied Solutions | Nonrecurring revenue
Disaggregation of Revenue [Line Items]
Revenue	504	490	976	976
Operating segments | Environmental & Applied Solutions | North America
Disaggregation of Revenue [Line Items]
Revenue	571	497	1,099	989
Operating segments | Environmental & Applied Solutions | Western Europe
Disaggregation of Revenue [Line Items]
Revenue	266	275	535	554
Operating segments | Environmental & Applied Solutions | Other developed markets
Disaggregation of Revenue [Line Items]
Revenue	32	30	64	59
Operating segments | Environmental & Applied Solutions | High-growth markets
Disaggregation of Revenue [Line Items]
Revenue	$ 354	$ 346	$ 687	$ 680

Revenue (Narrative) (Details)

Revenue (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2022	Jul. 02, 2021	Jul. 01, 2022	Jul. 02, 2021	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Revenue, OTLs and STLs	$ 117	$ 117	$ 241	$ 234
Contract with customer, assets, net	88		88		$ 75
Contract with customer, liabilities	$ 2,000		2,000		$ 1,800
Contract with customer, liabilities, revenue recognized			$ 995	$ 775

Revenue (Performance Obligation

Revenue (Performance Obligations) (Details) $ in Billions	Jul. 01, 2022 USD ($)
Revenue from Contract with Customer [Abstract]
Revenue, remaining performance obligation	$ 4.8
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-07-02
Revenue from Contract with Customer [Abstract]
Revenue, remaining performance obligation, percentage	60%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, expected timing of satisfaction, period	12 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-07-01
Revenue from Contract with Customer [Abstract]
Revenue, remaining performance obligation, percentage	24%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, expected timing of satisfaction, period	12 months

Segment Information (Narrative)

Segment Information (Narrative) (Details)	6 Months Ended
	Jul. 01, 2022 businessSegment
Segment Reporting [Abstract]
Number of segments reported	3

Segment Information (Segment Re

Segment Information (Segment Results) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2022	Jul. 02, 2021	Jul. 01, 2022	Jul. 02, 2021
Segment Reporting Information [Line Items]
Sales	$ 7,751	$ 7,218	$ 15,439	$ 14,076
Operating profit	2,205	2,005	4,377	4,002
Other
Segment Reporting Information [Line Items]
Operating profit	(76)	(68)	(144)	(133)
Life Sciences | Operating segments
Segment Reporting Information [Line Items]
Sales	3,967	3,734	7,849	7,280
Operating profit	1,174	1,144	2,292	2,295
Diagnostics | Operating segments
Segment Reporting Information [Line Items]
Sales	2,561	2,336	5,205	4,514
Operating profit	800	649	1,686	1,275
Environmental & Applied Solutions | Operating segments
Segment Reporting Information [Line Items]
Sales	1,223	1,148	2,385	2,282
Operating profit	$ 307	$ 280	$ 543	$ 565

Income Taxes (Summary of Danahe

Income Taxes (Summary of Danaher's Effective Income Tax Rate) (Details)	3 Months Ended		6 Months Ended
	Jul. 01, 2022	Jul. 02, 2021	Jul. 01, 2022	Jul. 02, 2021
Income Tax Disclosure [Abstract]
Effective tax rate	18.80%	16.80%	18.30%	17.60%

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2022	Jul. 02, 2021	Jul. 01, 2022	Jul. 02, 2021
Income Tax Disclosure [Abstract]
Federal statutory income tax rate, percent	21%	21%	21%	21%
Net tax benefits, impact, amount	$ 8	$ 76	$ 49	$ 120
Net tax benefits, impact percentage	0.40%	3.70%	1.20%	2.90%

Other Income (Expense), Net (Sc

Other Income (Expense), Net (Schedule of Other Income (Expense)) (Details) - USD ($) $ in Millions	3 Months Ended			6 Months Ended
	Jul. 01, 2022	Jul. 02, 2021	Apr. 02, 2021	Jul. 01, 2022	Jul. 02, 2021
Other Income and Expenses [Abstract]
Other components of net periodic benefit costs	$ 11	$ 11		$ 15	$ 22
Investment gains (losses):
Realized investment gains (losses)	27	11		64	38
Unrealized investment gains (losses)	(125)	75		(186)	164
Total investment gains (losses)	(98)	86		(122)	202
Gain on sale of product lines	0	0	$ 13	0	13
Total other income (expense), net	$ (87)	$ 97		$ (107)	$ 237

Other Income (Expense), Net (Na

Other Income (Expense), Net (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended			6 Months Ended		12 Months Ended
	Jul. 01, 2022	Jul. 02, 2021	Apr. 02, 2021	Jul. 01, 2022	Jul. 02, 2021	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Proceeds from sale of product lines, net of cash transferred and transaction costs			$ 26	$ 0	$ 26
Pretax gain on sale of product lines	$ 0	$ 0	13	0	13
Gain on sale of product lines, net of tax			$ 10
Divested, product lines, revenues						$ 88
Foreign Plan | Defined benefit pension plans
Defined Benefit Plan Disclosure [Line Items]
Settlement losses	$ 0	$ 0		10	$ 0
Settlement loss, after tax				$ 9

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets (Rollforward of Goodwill) (Details) $ in Millions	6 Months Ended
	Jul. 01, 2022 USD ($)
Goodwill [Roll Forward]
Balance, beginning of period	$ 41,184
Attributable to 2022 acquisitions	44
Adjustments due to finalization of purchase price allocations	(15)
Foreign currency translation and other	(1,937)
Balance, end of period	$ 39,276

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets (Goodwill by Segment) (Details) - USD ($) $ in Millions	Jul. 01, 2022	Dec. 31, 2021
Goodwill [Line Items]
Total goodwill	$ 39,276	$ 41,184
Operating segments | Life Sciences
Goodwill [Line Items]
Total goodwill	30,003	31,638
Operating segments | Diagnostics
Goodwill [Line Items]
Total goodwill	6,843	7,044
Operating segments | Environmental & Applied Solutions
Goodwill [Line Items]
Total goodwill	$ 2,430	$ 2,502

Goodwill and Other Intangible_5

Goodwill and Other Intangible Assets (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jul. 01, 2022	Jul. 01, 2022	Jul. 02, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Impairment charges	$ 9	$ 9	$ 10

Fair Value Measurements (Financ

Fair Value Measurements (Financial Assets and Liabilities Carried at Fair Value) (Details) - USD ($) $ in Millions	Jul. 01, 2022	Dec. 31, 2021
Assets:
Available-for-sale debt securities	$ 15	$ 20
Investment in equity securities	316	336
Cross-currency swap derivative contracts	823	50
Quoted Prices in Active Market (Level 1)
Assets:
Available-for-sale debt securities	0	0
Investment in equity securities	26	88
Cross-currency swap derivative contracts	0	0
Significant Other Observable Inputs (Level 2)
Assets:
Available-for-sale debt securities	15	20
Investment in equity securities	0	0
Cross-currency swap derivative contracts	823	50
Significant Unobservable Inputs (Level 3)
Assets:
Available-for-sale debt securities	0	0
Investment in equity securities	0	0
Cross-currency swap derivative contracts	$ 0	$ 0

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2022	Jul. 02, 2021	Jul. 01, 2022	Jul. 02, 2021	Dec. 31, 2021
Investment (losses) gains	$ (98)	$ 86	$ (122)	$ 202
Partnership
Equity method investments	$ 1,500		$ 1,500		$ 1,300

Fair Value Measurements (Carryi

Fair Value Measurements (Carrying Amounts and Fair Values of Other Financial Instruments) (Details) - USD ($) $ in Millions	Jul. 01, 2022	Dec. 31, 2021
Carrying Amount
Debt obligations:
Notes payable and current portion of long-term debt	$ 10	$ 8
Long-term debt	20,052	22,168
Fair Value
Debt obligations:
Notes payable and current portion of long-term debt	10	8
Long-term debt	$ 17,706	$ 22,796

Financing (Components of Debt)

Financing (Components of Debt) (Details) € in Millions, SFr in Millions, $ in Millions, ¥ in Billions	Jul. 01, 2022 USD ($)	Jul. 01, 2022 EUR (€)	Jul. 01, 2022 CHF (SFr)	Jul. 01, 2022 JPY (¥)	Jun. 30, 2022 EUR (€)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 EUR (€)	Dec. 31, 2021 CHF (SFr)	Dec. 31, 2021 JPY (¥)
Debt Instrument [Line Items]
Total debt	$ 20,062					$ 22,176
Less: currently payable	(10)					(8)
Long-term debt	20,052					22,168
Other
Debt Instrument [Line Items]
Total debt	21					25
Commercial paper | U.S. dollar-denominated commercial paper
Debt Instrument [Line Items]
Total debt	0					1,440
Commercial paper | Euro-denominated commercial paper
Debt Instrument [Line Items]
Total debt	2,008	€ 1,900				1,366	€ 1,200
Senior notes | Floating rate senior notes due 2022
Debt Instrument [Line Items]
Total debt	0					284
Aggregate principal amount | €		€ 250			€ 250		€ 250
Senior notes | 2.05% senior notes due 2022
Debt Instrument [Line Items]
Total debt	$ 700					$ 699
Interest rate of debt instrument	2.05%	2.05%	2.05%	2.05%		2.05%	2.05%	2.05%	2.05%
Senior notes | 1.7% senior notes due 2024
Debt Instrument [Line Items]
Total debt	$ 936					$ 1,021
Interest rate of debt instrument	1.70%	1.70%	1.70%	1.70%		1.70%	1.70%	1.70%	1.70%
Aggregate principal amount | €		€ 900					€ 900
Senior notes | 2.2% senior notes due 2024
Debt Instrument [Line Items]
Total debt	$ 698					$ 698
Interest rate of debt instrument	2.20%	2.20%	2.20%	2.20%		2.20%	2.20%	2.20%	2.20%
Senior notes | 3.35% senior notes due 2025
Debt Instrument [Line Items]
Total debt	$ 498					$ 498
Interest rate of debt instrument	3.35%	3.35%	3.35%	3.35%		3.35%	3.35%	3.35%	3.35%
Senior notes | 0.2% senior notes due 2026
Debt Instrument [Line Items]
Total debt	$ 1,298					$ 1,416
Interest rate of debt instrument	0.20%	0.20%	0.20%	0.20%		0.20%	0.20%	0.20%	0.20%
Aggregate principal amount | €		€ 1,300					€ 1,300
Senior notes | 2.1% senior notes due 2026
Debt Instrument [Line Items]
Total debt	$ 832					$ 907
Interest rate of debt instrument	2.10%	2.10%	2.10%	2.10%		2.10%	2.10%	2.10%	2.10%
Aggregate principal amount | €		€ 800					€ 800
Senior notes | 0.3% senior notes due 2027
Debt Instrument [Line Items]
Total debt	$ 227					$ 267
Interest rate of debt instrument	0.30%	0.30%	0.30%	0.30%		0.30%	0.30%	0.30%	0.30%
Aggregate principal amount | ¥				¥ 30.8					¥ 30.8
Senior notes | 1.2% senior notes due 2027
Debt Instrument [Line Items]
Total debt	$ 624					$ 680
Interest rate of debt instrument	1.20%	1.20%	1.20%	1.20%		1.20%	1.20%	1.20%	1.20%
Aggregate principal amount | €		€ 600					€ 600
Senior notes | 0.45% senior notes due 2028
Debt Instrument [Line Items]
Total debt	$ 1,296					$ 1,413
Interest rate of debt instrument	0.45%	0.45%	0.45%	0.45%		0.45%	0.45%	0.45%	0.45%
Aggregate principal amount | €		€ 1,300					€ 1,300
Senior notes | 2.6% senior notes due 2029
Debt Instrument [Line Items]
Total debt	$ 796					$ 795
Interest rate of debt instrument	2.60%	2.60%	2.60%	2.60%		2.60%	2.60%	2.60%	2.60%
Senior notes | 2.5% senior notes due 2030
Debt Instrument [Line Items]
Total debt	$ 834					$ 910
Interest rate of debt instrument	2.50%	2.50%	2.50%	2.50%		2.50%	2.50%	2.50%	2.50%
Aggregate principal amount | €		€ 800					€ 800
Senior notes | 0.75% senior notes due 2031
Debt Instrument [Line Items]
Total debt	$ 1,814					$ 1,980
Interest rate of debt instrument	0.75%	0.75%	0.75%	0.75%		0.75%	0.75%	0.75%	0.75%
Aggregate principal amount | €		€ 1,800					€ 1,800
Senior notes | 0.65% senior notes due 2032
Debt Instrument [Line Items]
Total debt	$ 392					$ 461
Interest rate of debt instrument	0.65%	0.65%	0.65%	0.65%		0.65%	0.65%	0.65%	0.65%
Aggregate principal amount | ¥				¥ 53.2					¥ 53.2
Senior notes | 1.35% senior notes due 2039
Debt Instrument [Line Items]
Total debt	$ 1,288					$ 1,406
Interest rate of debt instrument	1.35%	1.35%	1.35%	1.35%		1.35%	1.35%	1.35%	1.35%
Aggregate principal amount | €		€ 1,300					€ 1,300
Senior notes | 3.25% senior notes due 2039
Debt Instrument [Line Items]
Total debt	$ 890					$ 890
Interest rate of debt instrument	3.25%	3.25%	3.25%	3.25%		3.25%	3.25%	3.25%	3.25%
Senior notes | 4.375% senior notes due 2045
Debt Instrument [Line Items]
Total debt	$ 499					$ 499
Interest rate of debt instrument	4.375%	4.375%	4.375%	4.375%		4.375%	4.375%	4.375%	4.375%
Senior notes | 1.8% senior notes due 2049
Debt Instrument [Line Items]
Total debt	$ 773					$ 844
Interest rate of debt instrument	1.80%	1.80%	1.80%	1.80%		1.80%	1.80%	1.80%	1.80%
Aggregate principal amount | €		€ 750					€ 750
Senior notes | 3.4% senior notes due 2049
Debt Instrument [Line Items]
Total debt	$ 889					$ 889
Interest rate of debt instrument	3.40%	3.40%	3.40%	3.40%		3.40%	3.40%	3.40%	3.40%
Senior notes | 2.6% senior notes due 2050
Debt Instrument [Line Items]
Total debt	$ 980					$ 980
Interest rate of debt instrument	2.60%	2.60%	2.60%	2.60%		2.60%	2.60%	2.60%	2.60%
Senior notes | 2.8% senior unsecured notes due 2051
Debt Instrument [Line Items]
Total debt	$ 984					$ 983
Interest rate of debt instrument	2.80%	2.80%	2.80%	2.80%		2.80%	2.80%	2.80%	2.80%
Bonds | 0.5% senior bonds due 2023
Debt Instrument [Line Items]
Total debt	$ 563					$ 592
Interest rate of debt instrument	0.50%	0.50%	0.50%	0.50%		0.50%	0.50%	0.50%	0.50%
Aggregate principal amount | SFr			SFr 540					SFr 540
Bonds | 1.125% senior bonds due 2028
Debt Instrument [Line Items]
Total debt	$ 222					$ 233
Interest rate of debt instrument	1.125%	1.125%	1.125%	1.125%		1.125%	1.125%	1.125%	1.125%
Aggregate principal amount | SFr			SFr 210					SFr 210

Financing (Narrative) (Details)

Financing (Narrative) (Details) € in Millions	Jul. 01, 2022 EUR (€)	Jul. 01, 2022 USD ($)	Jun. 30, 2022 EUR (€)	Dec. 31, 2021 EUR (€)	Dec. 31, 2021 USD ($)
Debt Instrument [Line Items]
Debt discounts, premiums and debt issuance costs		$ 123,000,000			$ 130,000,000
Euro-denominated commercial paper | Commercial paper
Debt Instrument [Line Items]
Weighted average interest rate of long-term debt, interest rate	(0.20%)	(0.20%)
Weighted average maturity of long-term debt, at point in time	25 days
Floating rate senior notes due 2022 | Senior notes
Debt Instrument [Line Items]
Aggregate principal amount | €	€ 250		€ 250	€ 250
Long-term debt | Revolving credit facility | Five-Year Facility
Debt Instrument [Line Items]
Line of credit		$ 5,000,000,000

Hedging Transactions and Deri_3

Hedging Transactions and Derivative Financial Instruments (Summary of Notional Values and Pretax Impact in Fair Values of Net Investment Hedges and Cash Flow Hedges) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2022	Jul. 02, 2021	Jul. 01, 2022	Jul. 02, 2021
Derivative Instruments, Gain (Loss) [Line Items]
Amounts Reclassified from OCI	$ (213)	$ 51	$ (310)	$ (88)
Net investment hedges | Cross-currency contracts
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, original notional amount	3,875	2,875	3,875	2,875
Derivative, notional amount outstanding	3,000	2,000	3,000	2,000
Gain (Loss) Recognized in OCI	216	43	267	66
Amounts Reclassified from OCI	0	0	0	0
Net investment hedges | Foreign currency denominated debt
Derivative Instruments, Gain (Loss) [Line Items]
Nonderivative, notional amount	5,870	3,524	5,870	3,524
Net investment hedges, gain (loss), recognized in OCI	271	(36)	395	184
Amounts Reclassified from OCI	0	0	0	0
Cash flow hedges | Cross-currency contracts
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, original notional amount	4,000	4,000	4,000	4,000
Derivative, notional amount outstanding	4,000	4,000	4,000	4,000
Gain (Loss) Recognized in OCI	381	192	506	302
Amounts Reclassified from OCI	(224)	35	(340)	(117)
Cash flow hedges | Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, original notional amount	1,600	850	1,600	850
Derivative, notional amount outstanding	0	0	0	0
Gain (Loss) Recognized in OCI	0	0	0	0
Amounts Reclassified from OCI	1	1	2	1
Cash flow and net investment hedges
Derivative Instruments, Gain (Loss) [Line Items]
Original Notional Amount	15,345	11,249	15,345	11,249
Notional Amount Outstanding	12,870	9,524	12,870	9,524
Gain (Loss) Recognized in OCI	868	199	1,168	552
Amounts Reclassified from OCI	$ (223)	$ 36	$ (338)	$ (116)

Hedging Transactions and Deri_4

Hedging Transactions and Derivative Financial Instruments (Derivative and Nonderivative Debt Instruments) (Details) - Net investment hedges - USD ($) $ in Millions	Jul. 01, 2022	Dec. 31, 2021
Other long-term assets
Derivatives, Fair Value [Line Items]
Derivative assets	$ 823	$ 50
Long-term debt
Derivatives, Fair Value [Line Items]
Nonderivative hedging instruments	$ 5,870	$ 3,883

Defined Benefit Plans (Componen

Defined Benefit Plans (Components of Net Periodic Benefit Cost of Defined Benefit Pension Plans) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2022	Jul. 02, 2021	Jul. 01, 2022	Jul. 02, 2021
Defined benefit pension plans | U.S. pension benefits
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 0	$ 0	$ 0	$ 0
Interest cost	(14)	(11)	(27)	(23)
Expected return on plan assets	33	31	65	62
Amortization of actuarial loss	(9)	(11)	(18)	(22)
Net periodic benefit (cost)	10	9	20	17
Defined benefit pension plans | Foreign Plan
Defined Benefit Plan Disclosure [Line Items]
Service cost	(9)	(11)	(19)	(22)
Interest cost	(6)	(5)	(12)	(10)
Expected return on plan assets	8	11	18	22
Amortization of actuarial loss	(1)	(3)	(1)	(6)
Settlement losses recognized	0	0	(10)	0
Net periodic benefit (cost)	(8)	(8)	(24)	(16)
Other postretirement benefit plans
Defined Benefit Plan Disclosure [Line Items]
Service cost	0	0	0	0
Interest cost	0	0	(1)	(1)
Amortization of actuarial loss	0	(1)	0	(1)
Amortization of prior service credit	0	0	1	1
Net periodic benefit (cost)	$ 0	$ (1)	$ 0	$ (1)

Defined Benefit Plans (Narrativ

Defined Benefit Plans (Narrative) (Details) - Defined benefit pension plans - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2022	Jul. 02, 2021	Jul. 01, 2022	Jul. 02, 2021
Foreign Plan
Defined Benefit Plan Disclosure [Line Items]
Settlement loss	$ 0	$ 0	$ (10)	$ 0
Expected future employer contributions, current fiscal year	44		44
U.S. pension benefits
Defined Benefit Plan Disclosure [Line Items]
Expected future employer contributions, current fiscal year	$ 10		$ 10

Commitments and Contingencies (

Commitments and Contingencies (Narrative) (Details) - USD ($) $ in Millions	6 Months Ended
	Jul. 01, 2022	Dec. 31, 2021
Accrued warranty liabilities	$ 87	$ 97
Maximum
Standard product warranty period	10 years

Stockholders' Equity and Stoc_3

Stockholders' Equity and Stock-based Compensation (Narrative) (Details) $ / shares in Units, shares in Millions, $ in Millions			3 Months Ended		6 Months Ended		12 Months Ended
	Jul. 01, 2022 USD ($) $ / shares shares	Apr. 15, 2022 $ / shares shares	Jul. 01, 2022 USD ($) $ / shares shares	Jul. 02, 2021 shares	Jul. 01, 2022 USD ($) d $ / shares shares	Jul. 02, 2021 shares	Dec. 31, 2021	Jul. 16, 2013 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized shares to be repurchased								20
Remaining number of shares authorized to be repurchased	20		20		20
Common shares reserved for issuance under the 2007 Omnibus Incentive Plan, shares	44		44		44
RSU/PSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost | $	$ 292		$ 292		$ 292
Weighted average period for cost to be recognized	2 years
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost | $	$ 300		$ 300		$ 300
Weighted average period for cost to be recognized	2 years
Preferred stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock issued in connection with MCPS conversions			(1.7)	0	(1.7)	0
Preferred stock | Preferred stock series A
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred stock, dividend rate, percent		4.75%			4.75%		4.75%
Preferred stock, convertible, conversion rate		6.6632
Common stock issued in connection with MCPS conversions		11
Dividends paid (in usd per share) | $ / shares		$ 11.875
Preferred stock | 5.00% Mandatory Convertible Preferred Stock, Series B, without par value
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred stock, dividend rate, percent					5%		5%
Preferred stock, liquidation preference per share | $ / shares	$ 1,000		$ 1,000		$ 1,000
Preferred stock | 5.00% Mandatory Convertible Preferred Stock, Series B, without par value | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred stock, convertible, conversion rate	5.0130		5.0130		5.0130
Preferred stock | 5.00% Mandatory Convertible Preferred Stock, Series B, without par value | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred stock, convertible, conversion rate	6.1409		6.1409		6.1409
Common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Threshold consecutive trading days | d					20

Stockholders' Equity and Stoc_4

Stockholders' Equity and Stock-based Compensation (Summary of Share Activity) (Details) - shares shares in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2022	Jul. 02, 2021	Jul. 01, 2022	Jul. 02, 2021
Preferred stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance, beginning of period	3.4	3.4	3.4	3.4
Common stock issued in connection with Mandatory Convertible Preferred Stock conversions and LYONs’ conversions	(1.7)	0	(1.7)	0
Balance, end of period	1.7	3.4	1.7	3.4
Common stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance, beginning of period	857	853.7	855.7	851.3
Common stock-based compensation awards	0.4	0.7	1.7	2.2
Balance, end of period	868.4	854.4	868.4	854.4
Common stock | Common stock issued in connection with Liquid Yield Option Notes (“LYONs”) conversions
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued in connection with Mandatory Convertible Preferred Stock conversions and LYONs’ conversions	0	0	0	0.9
Common stock | Conversion of MCPS to common stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued in connection with Mandatory Convertible Preferred Stock conversions and LYONs’ conversions	11	0	11	0

Stockholders' Equity and Stoc_5

Stockholders' Equity and Stock-based Compensation (Components of Stock-Based Compensation Program) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2022	Jul. 02, 2021	Jul. 01, 2022	Jul. 02, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Pretax compensation expense	$ 101	$ 53	$ 181	$ 107
Income tax benefit	(21)	(11)	(37)	(22)
Total stock-based compensation expense, net of income taxes	80	42	144	85
RSU/PSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Pretax compensation expense	58	31	104	64
Income tax benefit	(12)	(6)	(21)	(13)
Total stock-based compensation expense, net of income taxes	46	25	83	51
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Pretax compensation expense	43	22	77	43
Income tax benefit	(9)	(5)	(16)	(9)
Total stock-based compensation expense, net of income taxes	$ 34	$ 17	$ 61	$ 34

Stockholders' Equity and Stoc_6

Stockholders' Equity and Stock-based Compensation (Accumulated Other Comprehensive Income) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2022	Jul. 02, 2021	Jul. 01, 2022	Jul. 02, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	$ (1,376)	$ (1,322)	$ (1,027)	$ (368)
Decrease (increase)	(1,009)	610	(1,215)	(197)
Income tax impact	(144)	(10)	(186)	(15)
Other comprehensive income (loss) before reclassifications, net of income taxes	(1,153)	600	(1,401)	(212)
Amounts Reclassified from OCI	(213)	51	(310)	(88)
Income tax impact	(3)	(4)	(7)	(7)
Reclassification adjustments, net of income taxes	(216)	47	(317)	(95)
Other comprehensive income (loss)	(1,369)	647	(1,718)	(307)
Ending balance	(2,745)	(675)	(2,745)	(675)
Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	(882)	(177)	(539)	745
Decrease (increase)	(1,390)	418	(1,721)	(499)
Income tax impact	(52)	(10)	(64)	(15)
Other comprehensive income (loss) before reclassifications, net of income taxes	(1,442)	408	(1,785)	(514)
Amounts Reclassified from OCI	0	0	0	0
Income tax impact	0	0	0	0
Reclassification adjustments, net of income taxes	0	0	0	0
Other comprehensive income (loss)	(1,442)	408	(1,785)	(514)
Ending balance	(2,324)	231	(2,324)	231
Pension and Postretirement Plan Benefit Adjustments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	(536)	(918)	(550)	(928)
Decrease (increase)	0	0	0	0
Income tax impact	0	0	0	0
Other comprehensive income (loss) before reclassifications, net of income taxes	0	0	0	0
Amounts Reclassified from OCI	10	15	28	28
Income tax impact	(3)	(4)	(7)	(7)
Reclassification adjustments, net of income taxes	7	11	21	21
Other comprehensive income (loss)	7	11	21	21
Ending balance	(529)	(907)	(529)	(907)
Cash Flow Hedge Adjustments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	42	(227)	62	(185)
Decrease (increase)	381	192	506	302
Income tax impact	(92)	0	(122)	0
Other comprehensive income (loss) before reclassifications, net of income taxes	289	192	384	302
Amounts Reclassified from OCI	(223)	36	(338)	(116)
Income tax impact	0	0	0	0
Reclassification adjustments, net of income taxes	(223)	36	(338)	(116)
Other comprehensive income (loss)	66	228	46	186
Ending balance	$ 108	$ 1	$ 108	$ 1